# Aripiprazole or Bupropion Augmentation Versus Switching to Bupropion in Treatment-Resistant Depression: A Risk-Benefit Analysis.

**DOI:** 10.4088/JCP.25m15863
**Authors:** ['William UMeyerson', 'Eric LRoss', 'Chris JKennedy', 'Rick HHoyle', 'JagpreetChhatwal', 'Philip SWang', 'Jordan WSmoller']
**Journal:** The Journal of clinical psychiatry
**Year:** 
**Scraped from:** DOI.org
**Scraped by:** agent_b
**Scraping date:** 2025-10-21T11:06:30.252316

## Abstract



## Full Text

## Abstract
objective: in treatment-resistant depression (trd), augmentation with aripiprazole (a-ari) or combination therapy by adding bupropion (c-bup) has been reported as more effective than switching to bupropion (s-bup), but c-bup risks falls in older adults, and a-ari risks weight gain and tardive dyskinesia (td). the aim of this study was to clarify whether the enhanced effectiveness outweighs such risks. methods: in this risk-benefit decision analysis, lifetime quality-adjusted life-years (qalys) following 1 year of a-ari or c-bup vs s-bup treatment were simulated in a health-state transition model tracking depression remission, falls, weight gain, and td, in age and baseline body mass index (bmi) subgroups, using data from the vast-d and optimum trials and other literature. qalys were converted to depression-free day-equivalents (dfds), the qalys gained from 1 day of remitted versus active depression. results: simulated adults aged 18–64 years experienced a net benefit of c-bup over s-bup of 20.7 dfds, equivalent to about 3 weeks of faster remission of depressive symptoms. in older adults, especially those aged 85+ years, this benefit over s-bup was partially but not fully offset by a risk of falls. in adults aged 18–64 years, a-ari was estimated to offer only 8.0 dfds after subtracting the expected harms from td, and this was further reduced to −22.8 dfds once metabolic harms were considered, in those overweight at baseline. overall, c-bup was preferred over a-ari in all subgroups except ages 85–89 years with bmi&lt;25, in whom a-ari was preferred. conclusion: in our model, c-bup better balanced efficacy and tolerability in trd in adults under 85 years than did s-bup or a-ari. a-ari was least-preferred in overweight adults. these results may inform shared decision-making and clinical guidelines. j clin psychiatry 2025;86(4):25m15863 author affiliations are listed at the end of this article. members only content this full article is available exclusively to professional tier members. subscribe now to unlock the html version and gain unlimited access to our entire library plus all pdfs. if you’re already a subscriber, please log in below to continue reading. subscribe now already a member? log in references (52) gaynes bn, lux l, gartlehner g, et al. defining treatment-resistant depression. depress anxiety . 2020;37(2):134–145. pubmed crossref zhdanava m, pilon d, ghelerter i, et al. the prevalence and national burden of treatment-resistant depression and major depressive disorder in the united states. j clin psychiatry . 2021;82(2):20m13699. pubmed crossref hantouche e, angst j, azorin jm. explained factors of suicide attempts in major depression. j affect disord . 2010;127(1-3):305–308. pubmed crossref dunner dl, rush aj, russell jm, et al. prospective, long-term, multicenter study of the naturalistic outcomes of patients with treatment-resistant depression. j clin psychiatry . 2006;67(5):688–695. pubmed crossref fekadu a, wooderson sc, markopoulo k, et al. what happens to patients with treatment-resistant depression? a systematic review of medium to long term outcome studies. j affect disord . 2009;116(1–2):4–11. pubmed crossref johnston km, powell lc, anderson im, et al. the burden of treatment-resistant depression: a systematic review of the economic and quality of life literature. j affect disord . 2019;242:195–210. pubmed crossref the national institute for health and care excellence. depression in adults: treatment and management. nice; 2022. https://www.nice.org.uk/guidance/ accessed september 30, 2024. gelenberg aj, freeman mp, markowitz jc, et al. american psychiatric association practice guideline for the treatment of patients with major depressive disorder, third edition. am j psychiatry . 2010;167(suppl):1–152. pubmed mcquaid jr, buelt a, capaldi v, et al. the management of major depressive disorder: synopsis of the 2022 u.s. department of veterans affairs and u.s. department of defense clinical practice guideline. ann intern med . 2022;175(10):1440–1451. pubmed crossref mohamed s, johnson gr, chen p, et al. effect of antidepressant switching vs augmentation on remission among patients with major depressive disorder unresponsive to antidepressant treatment: the vast-d randomized clinical trial. jama . 2017;318(2):132–145. pubmed crossref lenze ej, mulsant bh, roose sp, et al. antidepressant augmentation versus switch in treatment-resistant geriatric depression. n engl j med . 2023;388(12):1067–1079. pubmed crossref kenny ra, romero-ortuno r, kumar p. falls in older adults. medicine . 2017;45(1):28–33. haslam dw, james wpt. obesity. lancet . 2005;366(9492):1197–1209. pubmed crossref speyer h, westergaard c, albert n, et al. reversibility of antipsychotic-induced weight gain: a systematic review and meta-analysis. front endocrinol . 2021;12:577919. pubmed crossref kiriakakis v, bhatia kp, quinn np, et al. the natural history of tardive dystonia. a long-term follow-up study of 107 cases. brain . 1998;121(11):2053–2066. pubmed caroff sn, yeomans k, lenderking wr, et al. re-kinect: a prospective study of the presence and healthcare burden of tardive dyskinesia in clinical practice settings. j clin psychopharmacol . 2020;40(3):259–268. pubmed crossref yoon j, zisook s, park a, et al. comparing cost-effectiveness of aripiprazole augmentation with other “next-step” depression treatment strategies: a randomized clinical trial. j clin psychiatry . 2018;80(1):18m12294. pubmed crossref garrison lp, towse a, bresnahan bw. assessing a structured, quantitative health outcomes approach to drug risk-benefit analysis. health aff . 2007;26(3):684–695. pubmed crossref ramani sv, richard a. decision, irreversibility and flexibility: the irreversibility effect re-examined. theor decis . 1993;35(3):259–276. crossref husereau d, drummond m, augustovski f, et al. consolidated health economic evaluation reporting standards 2022 (cheers 2022) statement: updated reporting guidance for health economic evaluations . society for medical decision making; 2022. https://journals.sagepub.com/doi/full/10.1177/ accessed october 17, 2024 meyerson w, ross e, kennedy c, et al. appendix for aripiprazole or bupropion augmentation vs switching to bupropion in treatment resistant depression. 2025. https://osf.io/6czyp/ . accessed may 16, 2025 zisook s, johnson gr, hicks p, et al. continuation phase treatment outcomes for switching, combining, or augmenting strategies for treatment-resistant major depressive disorder: a vast-d report. depress anxiety . 2021;38(2):185–195. pubmed crossref bhaskaran k, dos-santos-silva i, leon da, et al. association of bmi with overall and cause-specific mortality: a population-based cohort study of 3.6 million adults in the uk. lancet diabetes endocrinol . 2018;6(12):944–953. pubmed crossref incerti d, jansen jp. hesim: health economic simulation modeling and decision analysis. 2021. doi :1 0.48550/arxiv.2102.09437 crossref attema ae, brouwer wbf, claxton k. discounting in economic evaluations. pharmacoeconomics . 2018;36(7):745–758. pubmed crossref carbon m, kane jm, leucht s, et al. tardive dyskinesia risk with first-and second-generation antipsychotics in comparative randomized controlled trials: a meta-analysis. world psychiatry . 2018;17(3):330–340. pubmed crossref morgenstern h, glazer wm. identifying risk factors for tardive dyskinesia among long-term outpatients maintained with neuroleptic medications: results of the yale tardive dyskinesia study. arch gen psychiatry . 1993;50(9):723–733. pubmed crossref woerner mg, alvir jmj, saltz bl, et al. prospective study of tardive dyskinesia in the elderly: rates and risk factors. aust j pharm . 1998;155(11):1521–1528. pubmed crossref tarsy d, lungu c, baldessarini rj. epidemiology of tardive dyskinesia before and during the era of modern antipsychotic drugs. handb clin neurol . 2011;100:601–616. pubmed crossref centers for disease control and prevention. web-based injury statistics query and reporting system (wisqars): cdc’s national center for injury prevention and control . 2002. accessed october 17, 2024. https://www.cdc.gov/injury/wisqars . tanner cm, caroff sn, cutler aj, et al. impact of possible tardive dyskinesia on physical wellness and social functioning: results from the real-world re-kinect study. j patient-rep outcomes . 2023;7(1):21. pubmed crossref ayyagari r, goldschmidt d, zhou m, et al. defining utility values for patients with tardive dyskinesia. curr med res opin . 2022;38(3):401–407. pubmed crossref mcevoy j, gandhi sk, rizio aa, et al. effect of tardive dyskinesia on quality of life in patients with bipolar disorder, major depressive disorder, and schizophrenia. qual life res . 2019;28(12):3303–3312. pubmed crossref judd ll, akiskal hs, maser jd, et al. a prospective 12-year study of subsyndromal and syndromal depressive symptoms in unipolar major depressive disorders. arch gen psychiatry . 1998;55(8):694–700. pubmed crossref mohiuddin s, payne k. utility values for adults with unipolar depression: systematic review and meta-analysis. med decis mak int j soc med decis mak . 2014;34(5):666–685. pubmed crossref revicki da, wood m. patient-assigned health state utilities for depression-related outcomes: differences by depression severity and antidepressant medications. j affect disord . 1998;48(1):25–36. pubmed crossref si l, winzenberg tm, de graaff b, palmer aj. a systematic review and meta-analysis of utility-based quality of life for osteoporosis-related conditions. osteoporos int j establ result coop eur found osteoporos natl osteoporos found usa . 2014;25(8):1987–1997. pubmed crossref ul-haq z, mackay df, fenwick e, pell jp. meta-analysis of the association between body mass index and health-related quality of life among adults, assessed by the sf-36. obes silver spring md . 2013;21(3):e322-e327 ross el, zivin k, maixner df. cost-effectiveness of electroconvulsive therapy vs pharmacotherapy/psychotherapy for treatment-resistant depression in the united states. jama psychiatry . 2018;75(7):713–722. pubmed crossref nuñez na, joseph b, pahwa m, et al. augmentation strategies for treatment resistant major depression: a systematic review and network meta-analysis. j affect disord . 2022;302:385–400. pubmed cheon ej, lee kh, park yw, et al. comparison of the efficacy and safety of aripiprazole versus bupropion augmentation in patients with major depressive disorder unresponsive to selective serotonin reuptake inhibitors: a randomized, prospective, open-label study. j clin psychopharmacol . 2017;37(2):193–199. pubmed crossref berman rm, thase me, trivedi mh, et al. long-term safety and tolerability of open-label aripiprazole augmentation of antidepressant therapy in major depressive disorder. neuropsychiatr dis treat . 2011;7:303–312. pubmed crossref barton bb, segger f, fischer k, et al. update on weight-gain caused by antipsychotics: a systematic review and meta-analysis. expert opin drug saf . 2020;19(3):295–314. pubmed crossref joo jh, lenze ej, mulsant bh, et al. risk factors for falls during treatment of late-life depression. j clin psychiatry . 2002;63(10):936–941. pubmed crossref jang sn, cho si, oh sw, et al. time since falling and fear of falling among community-dwelling elderly. int psychogeriatr . 2007;19(6):1072–1083. pubmed crossref katsoulis m, lai ag, diaz-ordaz k, et al. identifying adults at high-risk for change in weight and bmi in england: a longitudinal, large-scale, population-based cohort study using electronic health records. lancet diabetes endocrinol . 2021;9(10):681–694. pubmed crossref leucht s, cipriani a, spineli l, et al. comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. lancet . 2013;382(9896):951–962. pubmed crossref rhee tg, mohamed s, rosenheck ra. antipsychotic prescriptions among adults with major depressive disorder in office-based outpatient settings: national trends from 2006 to 2015. j clin psychiatry . 2018;79(2):17m11970. pubmed crossref gerhard t, akincigil a, correll cu, et al. national trends in second generation antipsychotic augmentation for non-psychotic depression. j clin psychiatry . 2014;75(5):490–497. pubmed crossref wang y, beydoun ma, min j, et al. has the prevalence of overweight, obesity and central obesity levelled off in the united states? trends, patterns, disparities, and future projections for the obesity epidemic. int j epidemiol . 2020;49(3):810–823. pubmed crossref luppino fs, de wit lm, bouvy pf, et al. overweight, obesity, and depression: a systematic review and meta-analysis of longitudinal studies. arch gen psychiatry . 2010;67(3):220–229. pubmed crossref fava m. lessons learned from the va augmentation and switching treatments for improving depression outcomes (vast-d) study. jama . 2017;318(2):126–128. pubmed crossref about the authors william u. meyerson, md, phd center for precision psychiatry, massachusetts general hospital, boston, massachusetts department of psychiatry, massachusetts general hospital/harvard medical school, boston, massachusetts corresponding author: william u. meyerson, md, phd, department of psychiatry, massachusetts general hospital/harvard medical school, simches research center, 185 cambridge st, boston, ma 02114 ( [email&#160;protected] ). view full profile eric l. ross, md department of psychiatry, larner college of medicine, university of vermont, burlington, vermont view full profile chris j. kennedy, phd, mpa center for precision psychiatry, massachusetts general hospital, boston, massachusetts department of psychiatry, massachusetts general hospital/harvard medical school, boston, massachusetts harvard medical school, boston, massachusetts view full profile rick h. hoyle, phd department of psychology and neuroscience, duke university, durham, north carolina view full profile jagpreet chhatwal, phd institute for technology assessment, massachusetts general hospital, harvard medical school, boston, massachusetts center for health decision science, harvard university, boston, massachusetts view full profile philip s. wang, md, drph division of pharmacoepidemiology and pharmacoeconomics, brigham and women’s hospital, harvard medical school, boston, massachusetts view full profile jordan w. smoller, md, scd center for precision psychiatry, massachusetts general hospital, boston, massachusetts department of psychiatry, massachusetts general hospital/harvard medical school, boston, massachusetts psychiatric and neurodevelopmental genetics unit, center for genomic medicine, massachusetts general hospital, boston, massachusetts view full profile buy pdf for $40 please sign in or purchase this pdf for $40. save share cite subscribe now already a member? login related news articles weekly mind reader: postpartum depression haunts one in six moms hair loss drug exacts a mental health toll decades in the making weekly mind reader: antidepressant use in pregnancy sponsored psychcase360: choosing the right long-acting injectable for patients with schizophrenia explore two real-world schizophrenia cases with roueen rafeyan, md and melissa vitale, pmhnp as they discuss challenges with medication adherence, transitioning to long-acting injectables (lais), and personalizing treatment strategies to improve patient outcomes. related jcp articles symptom network analysis of adhd and emotional symptoms in adults burnout in psychiatric doctors before and after the covid-19 pandemic effects of interpersonal and social rhythm therapy on suicidal ideation in adults with bipolar ii depression related pcc articles precision psychiatry for depression treatment predictors of depression response in a community ect clinic efficacy of glp-1 agonists in mental disorders vol 86 • 2025 • number 3 read the current issue original research treatment use and preference in a diverse sample of women with mood disorders original research klotho and matrix metalloproteinase-9 levels and their association with inhibitory dyscontrol in adolescents with first-episode major affective disorders original research niacin-induced response in early psychosis original research early ketamine response reduces suicidal events at 3 months letter to the editor suicide risk among patients with bipolar disorder: sleep disruption versus benzodiazepine use original research effect of nature videos on the burden of caregivers of patients with dementia view current issue related articles jcp original research association of immediate postpartum anxiety with postpartum depression october 15, 2025 the prevalence of immediate postpartum anxiety (ippa) in this population was 24%, and 7.4% for severe anxiety. among women with ippa, 31.2% developed postpartum depression. marie arnal , elodie-gaëlle ngameni , sarah tebeka , et al jcp original research depression at 2 months postpartum: results from the french national perinatal survey october 8, 2025 the prevalence of postpartum depression (ppd) at 2 months was 16.7%. factors associated with ppd included age ≤29 or ≥40 years, lower levels of health literacy, and a history... alexandra doncarli , virginie demiguel , camille le ray , et al jcp original research esmethadone (rel-1017) in patients with major depressive disorder and antidepressant tachyphylaxis october 6, 2025 esmethadone may be a potentially safe and effective adjunctive treatment for patients with mdd and antidepressant tachyphylaxis. clotilde guidetti , george i. papakostas , luca pani , et al expert consensus on aripiprazole lais in clinical practice read the full report subscribe to read more articles subscribe the journal of clinical psychiatry the primary care companion for cns disorders elsewhere: about advertisers media relations reprints & permissions contact us customer support follow us: x facebook instagram linkedin sign in join the email list subscribe now privacy policy terms of use physicians postgraduate press, inc. jcp issn: online 1555-2101, print 0160-6689 pcc issn: online 2155-7780, print 2155-7772 medfair.com us patent no. 684794 © copyright 2025 | physicians postgraduate press, inc. | lifelong learning for clinicians sitemap googletag.display("static-footer"); × // wait for klaviyo to load, then add custom properties document.addeventlistener('domcontentloaded', function() { // add custom properties to klaviyo tracking if (typeof klaviyo !== 'undefined') { // method a: set custom properties on the profile klaviyo.identify({ '$email': '', // add page-specific properties 'page_diseases': ["depression (mdd)"], 'primary_disease': "depression (mdd)", 'page_topics': ["depression (mdd)"], 'page_topics_count': 1, 'page_id': 220339, 'page_author': "tnq technologies", 'page_publish_date': "2025-09-22t04:00:33-05:00", 'journal': "jcp", 'last_page_view': '2025-10-21t06:06:30-05:00' }); // method b: track a custom event with page categories klaviyo.track('viewed content', { 'page_title': 'aripiprazole or bupropion augmentation versus switching to bupropion in treatment-resistant depression: a risk-benefit analysis', 'page_url': 'https://www.psychiatrist.com/jcp/aripiprazole-bupropion-augmentation-vs-switching-bupropion-treatment-resistant-depression-risk-benefit/', 'page_type': 'post', 'page_diseases': ["depression (mdd)"], 'primary_disease': "depression (mdd)", 'page_topics': ["depression (mdd)"], 'page_topics_count': 1, 'page_id': 220339, 'page_author': "tnq technologies", 'page_publish_date': "2025-09-22t04:00:33-05:00", 'journal': "jcp", 'timestamp': '2025-10-21t06:06:30-05:00' }); } }); (function () { var c = document.body.classname; c = c.replace(/woocommerce-no-js/, 'woocommerce-js'); document.body.classname = c; })(); var ajax = {"url":"https:\/\/www.psychiatrist.com\/wp-admin\/admin-ajax.php","nonce":"bee86d80ce","user":{"isloggedin":false,"user_type":"anon","membership_level":null,"subscribed_lists":[]},"klaviyo_lists":["sy2jg7","tkrrcd","qxiyyi","ufuy5l"]}; var wc_order_attribution = {"params":{"lifetime":1.0e-5,"session":30,"base64":false,"ajaxurl":"https:\/\/www.psychiatrist.com\/wp-admin\/admin-ajax.php","prefix":"wc_order_attribution_","allowtracking":true},"fields":{"source_type":"current.typ","referrer":"current_add.rf","utm_campaign":"current.cmp","utm_source":"current.src","utm_medium":"current.mdm","utm_content":"current.cnt","utm_id":"current.id","utm_term":"current.trm","utm_source_platform":"current.plt","utm_creative_format":"current.fmt","utm_marketing_tactic":"current.tct","session_entry":"current_add.ep","session_start_time":"current_add.fd","session_pages":"session.pgs","session_count":"udata.vst","user_agent":"udata.uag"}}; var kluser = {"current_user_email":"","commenter_email":""}; var psych_ajax = {"url":"https:\/\/www.psychiatrist.com\/wp-admin\/admin-ajax.php","nonce":"bee86d80ce","assets":{"spinner":"\/wp-content\/themes\/psych\/assets\/images\/spinner.gif","checkmark_white":"\/wp-content\/themes\/psych\/assets\/images\/icons\/check-white.svg","checkmark_tertiary":"\/wp-content\/themes\/psych\/assets\/images\/icons\/check-tertiary.svg","share":"\/wp-content\/themes\/psych\/assets\/images\/icons\/share.svg","quote":"\/wp-content\/themes\/psych\/assets\/images\/icons\/quote.svg","bookmark":"\/wp-content\/themes\/psych\/assets\/images\/icons\/bookmark-white.svg","bookmark_tertiary":"\/wp-content\/themes\/psych\/assets\/images\/icons\/bookmark-tertiary.svg"}}; var psych_ajax = {"url":"https:\/\/www.psychiatrist.com\/wp-admin\/admin-ajax.php","nonce":"bee86d80ce","assets":{"spinner":"\/wp-content\/themes\/psych\/assets\/images\/spinner.gif","checkmark_white":"\/wp-content\/themes\/psych\/assets\/images\/icons\/check-white.svg","checkmark_tertiary":"\/wp-content\/themes\/psych\/assets\/images\/icons\/check-tertiary.svg","share":"\/wp-content\/themes\/psych\/assets\/images\/icons\/share.svg","quote":"\/wp-content\/themes\/psych\/assets\/images\/icons\/quote.svg","bookmark":"\/wp-content\/themes\/psych\/assets\/images\/icons\/bookmark-white.svg","bookmark_tertiary":"\/wp-content\/themes\/psych\/assets\/images\/icons\/bookmark-tertiary.svg"}}; var ajax = {"url":"https:\/\/www.psychiatrist.com\/wp-admin\/admin-ajax.php","nonce":"bee86d80ce","user":{"isloggedin":false,"user_type":"anon","membership_level":null,"subscribed_lists":[]},"klaviyo_lists":["sy2jg7","tkrrcd","qxiyyi","ufuy5l"]}; var block = {"obj":"{\"terms\":[],\"dynamic_ads\":[{\"advertisement_gam_id\":\"sidebar-top\",\"ad_class\":\"gam-ad-slot\",\"mobile_hide_on\":true,\"mobile_max_width\":\"874\",\"div_id\":\"sidebar-top\",\"type\":\"square\",\"slot_targeting\":{\"position\":null,\"type\":\"square\"}}],\"config\":{\"ad-banner\":{\"type\":\"banner\",\"slug\":\"ad-banner\",\"sizes\":{\"small-banner\":{\"label\":\"small banner\",\"slug\":\"small-banner\",\"size\":{\"width\":320,\"height\":50}},\"medium-banner\":{\"label\":\"medium banner\",\"slug\":\"medium-banner\",\"size\":{\"width\":728,\"height\":90}}}},\"ad-square\":{\"type\":\"square\",\"slug\":\"ad-square\",\"sizes\":{\"square\":{\"label\":\"square\",\"slug\":\"square\",\"size\":{\"width\":300,\"height\":250}}}},\"ad-banner-square\":{\"type\":\"banner \\\/ square (mobile \\\/ desktop)\",\"slug\":\"ad-banner-square\",\"sizes\":{\"banner-square\":{\"label\":\"banner \\\/ square (mobile \\\/ desktop)\",\"slug\":\"banner-square\",\"size\":{\"width\":300,\"height\":250}}}},\"ad-rectangle\":{\"type\":\"rectangle\",\"slug\":\"ad-rectangle\",\"sizes\":{\"rectangle\":{\"label\":\"rectangle\",\"slug\":\"rectangle\",\"size\":{\"width\":300,\"height\":600}}}}},\"page_targeting\":{\"page_name\":\"aripiprazole or bupropion augmentation versus switching to bupropion in treatment-resistant depression: a risk-benefit analysis\",\"site_section\":\"academic_article\",\"post_type\":\"post\",\"post_id\":220339,\"permalink\":\"https:\\\/\\\/www.psychiatrist.com\\\/jcp\\\/aripiprazole-bupropion-augmentation-vs-switching-bupropion-treatment-resistant-depression-risk-benefit\\\/\",\"categories\":[\"depression\",\"early-career-psychiatrists\",\"original-research\"],\"journal\":\"jcp\"},\"page_ads\":[]}"}; var ajax = {"url":"https:\/\/www.psychiatrist.com\/wp-admin\/admin-ajax.php","nonce":"bee86d80ce","user":{"isloggedin":false,"user_type":"anon","membership_level":null,"subscribed_lists":[]},"klaviyo_lists":["sy2jg7","tkrrcd","qxiyyi","ufuy5l"]}; var block = {"obj":"{\"terms\":[],\"dynamic_ads\":[{\"advertisement_gam_id\":\"sidebar-top\",\"ad_class\":\"gam-ad-slot\",\"mobile_hide_on\":true,\"mobile_max_width\":\"874\",\"div_id\":\"sidebar-top\",\"type\":\"square\",\"slot_targeting\":{\"position\":null,\"type\":\"square\"}},{\"advertisement_gam_id\":\"sidebar-bottom\",\"ad_class\":\"gam-ad-slot\",\"mobile_hide_on\":true,\"mobile_max_width\":\"874\",\"div_id\":\"sidebar-bottom\",\"type\":\"square\",\"slot_targeting\":{\"position\":null,\"type\":\"square\"}}],\"config\":{\"ad-banner\":{\"type\":\"banner\",\"slug\":\"ad-banner\",\"sizes\":{\"small-banner\":{\"label\":\"small banner\",\"slug\":\"small-banner\",\"size\":{\"width\":320,\"height\":50}},\"medium-banner\":{\"label\":\"medium banner\",\"slug\":\"medium-banner\",\"size\":{\"width\":728,\"height\":90}}}},\"ad-square\":{\"type\":\"square\",\"slug\":\"ad-square\",\"sizes\":{\"square\":{\"label\":\"square\",\"slug\":\"square\",\"size\":{\"width\":300,\"height\":250}}}},\"ad-banner-square\":{\"type\":\"banner \\\/ square (mobile \\\/ desktop)\",\"slug\":\"ad-banner-square\",\"sizes\":{\"banner-square\":{\"label\":\"banner \\\/ square (mobile \\\/ desktop)\",\"slug\":\"banner-square\",\"size\":{\"width\":300,\"height\":250}}}},\"ad-rectangle\":{\"type\":\"rectangle\",\"slug\":\"ad-rectangle\",\"sizes\":{\"rectangle\":{\"label\":\"rectangle\",\"slug\":\"rectangle\",\"size\":{\"width\":300,\"height\":600}}}}},\"page_targeting\":{\"page_name\":\"aripiprazole or bupropion augmentation versus switching to bupropion in treatment-resistant depression: a risk-benefit analysis\",\"site_section\":\"academic_article\",\"post_type\":\"post\",\"post_id\":220339,\"permalink\":\"https:\\\/\\\/www.psychiatrist.com\\\/jcp\\\/aripiprazole-bupropion-augmentation-vs-switching-bupropion-treatment-resistant-depression-risk-benefit\\\/\",\"categories\":[\"depression\",\"early-career-psychiatrists\",\"original-research\"],\"journal\":\"jcp\"},\"page_ads\":[]}"}; window.usercontext = { isloggedin: false, hasemail: false, usertype: '' }; (function(){function c(){var b=a.contentdocument||a.contentwindow.document;if(b){var d=b.createelement('script');d.innerhtml="window.__cf$cv$params={r:'9920492c3c370384',t:'mtc2mta0ndc4oq=='};var a=document.createelement('script');a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getelementsbytagname('head')[0].appendchild(a);";b.getelementsbytagname('head')[0].appendchild(d)}}if(document.body){var a=document.createelement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendchild(a);if('loading'!==document.readystate)c();else if(window.addeventlistener)document.addeventlistener('domcontentloaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readystate&&(document.onreadystatechange=e,c())}}}})();

## Introduction
#32373c;color:#fff;text-decoration:none} :root{--wp--preset--aspect-ratio--square: 1;--wp--preset--aspect-ratio--4-3: 4/3;--wp--preset--aspect-ratio--3-4: 3/4;--wp--preset--aspect-ratio--3-2: 3/2;--wp--preset--aspect-ratio--2-3: 2/3;--wp--preset--aspect-ratio--16-9: 16/9;--wp--preset--aspect-ratio--9-16: 9/16;--wp--preset--color--black: #000000;--wp--preset--color--cyan-bluish-gray: #abb8c3;--wp--preset--color--white: #ffffff;--wp--preset--color--pale-pink: #f78da7;--wp--preset--color--vivid-red: #cf2e2e;--wp--preset--color--luminous-vivid-orange: #ff6900;--wp--preset--color--luminous-vivid-amber: #fcb900;--wp--preset--color--light-green-cyan: #7bdcb5;--wp--preset--color--vivid-green-cyan: #00d084;--wp--preset--color--pale-cyan-blue: #8ed1fc;--wp--preset--color--vivid-cyan-blue: #0693e3;--wp--preset--color--vivid-purple: #9b51e0;--wp--preset--gradient--vivid-cyan-blue-to-vivid-purple: linear-gradient(135deg,rgba(6,147,227,1) 0%,rgb(155,81,224) 100%);--wp--preset--gradient--light-green-cyan-to-vivid-green-cyan: linear-gradient(135deg,rgb(122,220,180) 0%,rgb(0,208,130) 100%);--wp--preset--gradient--luminous-vivid-amber-to-luminous-vivid-orange: linear-gradient(135deg,rgba(252,185,0,1) 0%,rgba(255,105,0,1) 100%);--wp--preset--gradient--luminous-vivid-orange-to-vivid-red: linear-gradient(135deg,rgba(255,105,0,1) 0%,rgb(207,46,46) 100%);--wp--preset--gradient--very-light-gray-to-cyan-bluish-gray: linear-gradient(135deg,rgb(238,238,238) 0%,rgb(169,184,195) 100%);--wp--preset--gradient--cool-to-warm-spectrum: linear-gradient(135deg,rgb(74,234,220) 0%,rgb(151,120,209) 20%,rgb(207,42,186) 40%,rgb(238,44,130) 60%,rgb(251,105,98) 80%,rgb(254,248,76) 100%);--wp--preset--gradient--blush-light-purple: linear-gradient(135deg,rgb(255,206,236) 0%,rgb(152,150,240) 100%);--wp--preset--gradient--blush-bordeaux: linear-gradient(135deg,rgb(254,205,165) 0%,rgb(254,45,45) 50%,rgb(107,0,62) 100%);--wp--preset--gradient--luminous-dusk: linear-gradient(135deg,rgb(255,203,112) 0%,rgb(199,81,192) 50%,rgb(65,88,208) 100%);--wp--preset--gradient--pale-ocean: linear-gradient(135deg,rgb(255,245,203) 0%,rgb(182,227,212) 50%,rgb(51,167,181) 100%);--wp--preset--gradient--electric-grass: linear-gradient(135deg,rgb(202,248,128) 0%,rgb(113,206,126) 100%);--wp--preset--gradient--midnight: linear-gradient(135deg,rgb(2,3,129) 0%,rgb(40,116,252) 100%);--wp--preset--font-size--small: 13px;--wp--preset--font-size--medium: 20px;--wp--preset--font-size--large: 36px;--wp--preset--font-size--x-large: 42px;--wp--preset--spacing--20: 0.44rem;--wp--preset--spacing--30: 0.67rem;--wp--preset--spacing--40: 1rem;--wp--preset--spacing--50: 1.5rem;--wp--preset--spacing--60: 2.25rem;--wp--preset--spacing--70: 3.38rem;--wp--preset--spacing--80: 5.06rem;--wp--preset--shadow--natural: 6px 6px 9px rgba(0, 0, 0, 0.2);--wp--preset--shadow--deep: 12px 12px 50px rgba(0, 0, 0, 0.4);--wp--preset--shadow--sharp: 6px 6px 0px rgba(0, 0, 0, 0.2);--wp--preset--shadow--outlined: 6px 6px 0px -3px rgba(255, 255, 255, 1), 6px 6px rgba(0, 0, 0, 1);--wp--preset--shadow--crisp: 6px 6px 0px rgba(0, 0, 0, 1);}:where(.is-layout-flex){gap: 0.5em;}:where(.is-layout-grid){gap: 0.5em;}body .is-layout-flex{display: flex;}.is-layout-flex{flex-wrap: wrap;align-items: center;}.is-layout-flex > :is(*, div){margin: 0;}body .is-layout-grid{display: grid;}.is-layout-grid > :is(*, div){margin: 0;}:where(.wp-block-columns.is-layout-flex){gap: 2em;}:where(.wp-block-columns.is-layout-grid){gap: 2em;}:where(.wp-block-post-template.is-layout-flex){gap: 1.25em;}:where(.wp-block-post-template.is-layout-grid){gap: 1.25em;}.has-black-color{color: var(--wp--preset--color--black) !important;}.has-cyan-bluish-gray-color{color: var(--wp--preset--color--cyan-bluish-gray) !important;}.has-white-color{color: var(--wp--preset--color--white) !important;}.has-pale-pink-color{color: var(--wp--preset--color--pale-pink) !important;}.has-vivid-red-color{color: var(--wp--preset--color--vivid-red) !important;}.has-luminous-vivid-orange-color{color: var(--wp--preset--color--luminous-vivid-orange) !important;}.has-luminous-vivid-amber-color{color: var(--wp--preset--color--luminous-vivid-amber) !important;}.has-light-green-cyan-color{color: var(--wp--preset--color--light-green-cyan) !important;}.has-vivid-green-cyan-color{color: var(--wp--preset--color--vivid-green-cyan) !important;}.has-pale-cyan-blue-color{color: var(--wp--preset--color--pale-cyan-blue) !important;}.has-vivid-cyan-blue-color{color: var(--wp--preset--color--vivid-cyan-blue) !important;}.has-vivid-purple-color{color: var(--wp--preset--color--vivid-purple) !important;}.has-black-background-color{background-color: var(--wp--preset--color--black) !important;}.has-cyan-bluish-gray-background-color{background-color: var(--wp--preset--color--cyan-bluish-gray) !important;}.has-white-background-color{background-color: var(--wp--preset--color--white) !important;}.has-pale-pink-background-color{background-color: var(--wp--preset--color--pale-pink) !important;}.has-vivid-red-background-color{background-color: var(--wp--preset--color--vivid-red) !important;}.has-luminous-vivid-orange-background-color{background-color: var(--wp--preset--color--luminous-vivid-orange) !important;}.has-luminous-vivid-amber-background-color{background-color: var(--wp--preset--color--luminous-vivid-amber) !important;}.has-light-green-cyan-background-color{background-color: var(--wp--preset--color--light-green-cyan) !important;}.has-vivid-green-cyan-background-color{background-color: var(--wp--preset--color--vivid-green-cyan) !important;}.has-pale-cyan-blue-background-color{background-color: var(--wp--preset--color--pale-cyan-blue) !important;}.has-vivid-cyan-blue-background-color{background-color: var(--wp--preset--color--vivid-cyan-blue) !important;}.has-vivid-purple-background-color{background-color: var(--wp--preset--color--vivid-purple) !important;}.has-black-border-color{border-color: var(--wp--preset--color--black) !important;}.has-cyan-bluish-gray-border-color{border-color: var(--wp--preset--color--cyan-bluish-gray) !important;}.has-white-border-color{border-color: var(--wp--preset--color--white) !important;}.has-pale-pink-border-color{border-color: var(--wp--preset--color--pale-pink) !important;}.has-vivid-red-border-color{border-color: var(--wp--preset--color--vivid-red) !important;}.has-luminous-vivid-orange-border-color{border-color: var(--wp--preset--color--luminous-vivid-orange) !important;}.has-luminous-vivid-amber-border-color{border-color: var(--wp--preset--color--luminous-vivid-amber) !important;}.has-light-green-cyan-border-color{border-color: var(--wp--preset--color--light-green-cyan) !important;}.has-vivid-green-cyan-border-color{border-color: var(--wp--preset--color--vivid-green-cyan) !important;}.has-pale-cyan-blue-border-color{border-color: var(--wp--preset--color--pale-cyan-blue) !important;}.has-vivid-cyan-blue-border-color{border-color: var(--wp--preset--color--vivid-cyan-blue) !important;}.has-vivid-purple-border-color{border-color: var(--wp--preset--color--vivid-purple) !important;}.has-vivid-cyan-blue-to-vivid-purple-gradient-background{background: var(--wp--preset--gradient--vivid-cyan-blue-to-vivid-purple) !important;}.has-light-green-cyan-to-vivid-green-cyan-gradient-background{background: var(--wp--preset--gradient--light-green-cyan-to-vivid-green-cyan) !important;}.has-luminous-vivid-amber-to-luminous-vivid-orange-gradient-background{background: var(--wp--preset--gradient--luminous-vivid-amber-to-luminous-vivid-orange) !important;}.has-luminous-vivid-orange-to-vivid-red-gradient-background{background: var(--wp--preset--gradient--luminous-vivid-orange-to-vivid-red) !important;}.has-very-light-gray-to-cyan-bluish-gray-gradient-background{background: var(--wp--preset--gradient--very-light-gray-to-cyan-bluish-gray) !important;}.has-cool-to-warm-spectrum-gradient-background{background: var(--wp--preset--gradient--cool-to-warm-spectrum) !important;}.has-blush-light-purple-gradient-background{background: var(--wp--preset--gradient--blush-light-purple) !important;}.has-blush-bordeaux-gradient-background{background: var(--wp--preset--gradient--blush-bordeaux) !important;}.has-luminous-dusk-gradient-background{background: var(--wp--preset--gradient--luminous-dusk) !important;}.has-pale-ocean-gradient-background{background: var(--wp--preset--gradient--pale-ocean) !important;}.has-electric-grass-gradient-background{background: var(--wp--preset--gradient--electric-grass) !important;}.has-midnight-gradient-background{background: var(--wp--preset--gradient--midnight) !important;}.has-small-font-size{font-size: var(--wp--preset--font-size--small) !important;}.has-medium-font-size{font-size: var(--wp--preset--font-size--medium) !important;}.has-large-font-size{font-size: var(--wp--preset--font-size--large) !important;}.has-x-large-font-size{font-size: var(--wp--preset--font-size--x-large) !important;} :where(.wp-block-post-template.is-layout-flex){gap: 1.25em;}:where(.wp-block-post-template.is-layout-grid){gap: 1.25em;} :where(.wp-block-columns.is-layout-flex){gap: 2em;}:where(.wp-block-columns.is-layout-grid){gap: 2em;} :root :where(.wp-block-pullquote){font-size: 1.5em;line-height: 1.6;} .woocommerce form .form-row .required { visibility: visible; } var wc_add_to_cart_params = {"ajax_url":"\/wp-admin\/admin-ajax.php","wc_ajax_url":"\/?wc-ajax=%%endpoint%%","i18n_view_cart":"view cart","cart_url":"https:\/\/www.psychiatrist.com\/cart\/","is_cart":"","cart_redirect_after_add":"no"}; var woocommerce_params = {"ajax_url":"\/wp-admin\/admin-ajax.php","wc_ajax_url":"\/?wc-ajax=%%endpoint%%","i18n_password_show":"show password","i18n_password_hide":"hide password"}; console.warn( "scripts that have a dependency on [wc-settings, wc-blocks-checkout] must be loaded in the footer, klaviyo-klaviyo-checkout-block-editor-script was registered to load in the header, but has been switched to load in the footer instead. see https://github.com/woocommerce/woocommerce-gutenberg-products-block/pull/5059" ); console.warn( "scripts that have a dependency on [wc-settings, wc-blocks-checkout] must be loaded in the footer, klaviyo-klaviyo-checkout-block-view-script was registered to load in the header, but has been switched to load in the footer instead. see https://github.com/woocommerce/woocommerce-gutenberg-products-block/pull/5059" ); var gam = {"page_targeting":"{\"page_name\":\"aripiprazole or bupropion augmentation versus switching to bupropion in treatment-resistant depression: a risk-benefit analysis\",\"site_section\":\"academic_article\",\"post_type\":\"post\",\"post_id\":220339,\"permalink\":\"https:\\\/\\\/www.psychiatrist.com\\\/jcp\\\/aripiprazole-bupropion-augmentation-vs-switching-bupropion-treatment-resistant-depression-risk-benefit\\\/\",\"categories\":[\"depression\",\"early-career-psychiatrists\",\"original-research\"],\"journal\":\"jcp\"}"}; var bigdatacloud_key = {"key":""}; var myajax = {"ajaxurl":"https:\/\/www.psychiatrist.com\/wp-admin\/admin-ajax.php"}; {"@context":"https://schema.org","@type":"scholarlyarticle","mainentityofpage":{"@type":"webpage","@id":"https://www.psychiatrist.com/jcp/aripiprazole-bupropion-augmentation-vs-switching-bupropion-treatment-resistant-depression-risk-benefit/"},"headline":"aripiprazole or bupropion augmentation versus switching to bupropion in treatment-resistant depression: a risk-benefit analysis","image":{"@type":"imageobject","url":"https://www.psychiatrist.com/wp-content/uploads/2025/09/jcp_treatment-resistant-depression-bupropion.jpg","width":1200,"height":800},"datepublished":"2025-09-22t04:00:33+0000","datemodified":"2025-09-21t21:32:28+0000","author":{"@type":"person","name":"tnq technologies","url":"https://www.psychiatrist.com/author/aboutpsychtnq-co-in"},"publisher":{"@type":"organization","name":"psychiatrist.com","logo":{"@type":"imageobject","url":"https://www.psychiatrist.com/wp-content/uploads/2025/09/jcp_treatment-resistant-depression-bupropion.jpg"}},"description":"in this model, augmentation with bupropion better balanced efficacy and tolerability in trd in adults under 85 than did switching to bupropion or augmentation with aripiprazole. augmentation with aripiprazole was least-preferred in overweight adults."} {"@context":"https:\/\/schema.org","@type":"breadcrumblist","itemlistelement":[{"@type":"listitem","position":1,"item":{"@id":"https:\/\/www.psychiatrist.com\/","name":"home"}},{"@type":"listitem","position":2,"item":{"@id":"https:\/\/www.psychiatrist.com\/jcp\/aripiprazole-bupropion-augmentation-vs-switching-bupropion-treatment-resistant-depression-risk-benefit\/","name":"aripiprazole or bupropion augmentation versus switching to bupropion in treatment-resistant depression: a risk-benefit analysis"}}]} .woocommerce-product-gallery{ opacity: 1 !important; } skip to content jcp pcc news cme about authors &#038; reviewers sign in subscribe search advanced search menu jcp pcc news cme about authors &#038; reviewers sign in subscribe sign in subscribe clinical topics view all addiction adhd alzheimer&#8217;s disease anxiety bipolar disorder depression movement disorders neurology ocd psychopharmacology ptsd and trauma schizophrenia/schizoaffective disorders sleep tardive dyskinesia view all collections view all academic highlights auvelity: information from industry banner alzheimer&#8217;s institute clinical &#038; practical psychopharmacology early career psychiatrists focus on childhood and adolescent mental health focus on geriatric psychiatry focus on psychotherapy focus on suicide focus on psychosis focus on women’s mental health rounds in the general hospital uzedy: information from industry view all back to top open menu download pdf save share cite reprints sections methods results discussion article information clinical points the journal of clinical psychiatry depression (mdd) original research early career psychiatrists september 22, 2025 aripiprazole or bupropion augmentation versus switching to bupropion in treatment-resistant depression: a risk-benefit analysis william u. meyerson, md, phd ; eric l. ross, md ; chris j. kennedy, phd, mpa ; rick h. hoyle, phd ; jagpreet chhatwal, phd ; philip s. wang, md, drph ; jordan w. smoller, md, scd j clin psychiatry 2025;86(4):25m15863 abstract objective: in treatment-resistant depression (trd), augmentation with aripiprazole (a-ari) or combination therapy by adding bupropion (c-bup) has been reported as more effective than switching to bupropion (s-bup), but c-bup risks falls in older adults, and a-ari risks weight gain and tardive dyskinesia (td). the aim of this study was to clarify whether the enhanced effectiveness outweighs such risks. methods: in this risk-benefit decision analysis, lifetime quality-adjusted life-years (qalys) following 1 year of a-ari or c-bup vs s-bup treatment were simulated in a health-state transition model tracking depression remission, falls, weight gain, and td, in age and baseline body mass index (bmi) subgroups, using data from the vast-d and optimum trials and other literature. qalys were converted to depression-free day-equivalents (dfds), the qalys gained from 1 day of remitted versus active depression. results: simulated adults aged 18–64 years experienced a net benefit of c-bup over s-bup of 20.7 dfds, equivalent to about 3 weeks of faster remission of depressive symptoms. in older adults, especially those aged 85+ years, this benefit over s-bup was partially but not fully offset by a risk of falls. in adults aged 18–64 years, a-ari was estimated to offer only 8.0 dfds after subtracting the expected harms from td, and this was further reduced to −22.8 dfds once metabolic harms were considered, in those overweight at baseline. overall, c-bup was preferred over a-ari in all subgroups except ages 85–89 years with bmi&lt;25, in whom a-ari was preferred. conclusion: in our model, c-bup better balanced efficacy and tolerability in trd in adults under 85 years than did s-bup or a-ari. a-ari was least-preferred in overweight adults. these results may inform shared decision-making and clinical guidelines. j clin psychiatry 2025;86(4):25m15863 author affiliations are listed at the end of this article. members only content this full article is available exclusively to professional tier members. subscribe now to unlock the html version and gain unlimited access to our entire library plus all pdfs. if you’re already a subscriber, please log in below to continue reading. subscribe now already a member? log in references (52) gaynes bn, lux l, gartlehner g, et al. defining treatment-resistant depression. depress anxiety . 2020;37(2):134–145. pubmed crossref zhdanava m, pilon d, ghelerter i, et al. the prevalence and national burden of treatment-resistant depression and major depressive disorder in the united states. j clin psychiatry . 2021;82(2):20m13699. pubmed crossref hantouche e, angst j, azorin jm. explained factors of suicide attempts in major depression. j affect disord . 2010;127(1-3):305–308. pubmed crossref dunner dl, rush aj, russell jm, et al. prospective, long-term, multicenter study of the naturalistic outcomes of patients with treatment-resistant depression. j clin psychiatry . 2006;67(5):688–695. pubmed crossref fekadu a, wooderson sc, markopoulo k, et al. what happens to patients with treatment-resistant depression? a systematic review of medium to long term outcome studies. j affect disord . 2009;116(1–2):4–11. pubmed crossref johnston km, powell lc, anderson im, et al. the burden of treatment-resistant depression: a systematic review of the economic and quality of life literature. j affect disord . 2019;242:195–210. pubmed crossref the national institute for health and care excellence. depression in adults: treatment and management. nice; 2022. https://www.nice.org.uk/guidance/ accessed september 30, 2024. gelenberg aj, freeman mp, markowitz jc, et al. american psychiatric association practice guideline for the treatment of patients with major depressive disorder, third edition. am j psychiatry . 2010;167(suppl):1–152. pubmed mcquaid jr, buelt a, capaldi v, et al. the management of major depressive disorder: synopsis of the 2022 u.s. department of veterans affairs and u.s. department of defense clinical practice guideline. ann intern med . 2022;175(10):1440–1451. pubmed crossref mohamed s, johnson gr, chen p, et al. effect of antidepressant switching vs augmentation on remission among patients with major depressive disorder unresponsive to antidepressant treatment: the vast-d randomized clinical trial. jama . 2017;318(2):132–145. pubmed crossref lenze ej, mulsant bh, roose sp, et al. antidepressant augmentation versus switch in treatment-resistant geriatric depression. n engl j med . 2023;388(12):1067–1079. pubmed crossref kenny ra, romero-ortuno r, kumar p. falls in older adults. medicine . 2017;45(1):28–33. haslam dw, james wpt. obesity. lancet . 2005;366(9492):1197–1209. pubmed crossref speyer h, westergaard c, albert n, et al. reversibility of antipsychotic-induced weight gain: a systematic review and meta-analysis. front endocrinol . 2021;12:577919. pubmed crossref kiriakakis v, bhatia kp, quinn np, et al. the natural history of tardive dystonia. a long-term follow-up study of 107 cases. brain . 1998;121(11):2053–2066. pubmed caroff sn, yeomans k, lenderking wr, et al. re-kinect: a prospective study of the presence and healthcare burden of tardive dyskinesia in clinical practice settings. j clin psychopharmacol . 2020;40(3):259–268. pubmed crossref yoon j, zisook s, park a, et al. comparing cost-effectiveness of aripiprazole augmentation with other “next-step” depression treatment strategies: a randomized clinical trial. j clin psychiatry . 2018;80(1):18m12294. pubmed crossref garrison lp, towse a, bresnahan bw. assessing a structured, quantitative health outcomes approach to drug risk-benefit analysis. health aff . 2007;26(3):684–695. pubmed crossref ramani sv, richard a. decision, irreversibility and flexibility: the irreversibility effect re-examined. theor decis . 1993;35(3):259–276. crossref husereau d, drummond m, augustovski f, et al. consolidated health economic evaluation reporting standards 2022 (cheers 2022) statement: updated reporting guidance for health economic evaluations . society for medical decision making; 2022. https://journals.sagepub.com/doi/full/10.1177/ accessed october 17, 2024 meyerson w, ross e, kennedy c, et al. appendix for aripiprazole or bupropion augmentation vs switching to bupropion in treatment resistant depression. 2025. https://osf.io/6czyp/ . accessed may 16, 2025 zisook s, johnson gr, hicks p, et al. continuation phase treatment outcomes for switching, combining, or augmenting strategies for treatment-resistant major depressive disorder: a vast-d report. depress anxiety . 2021;38(2):185–195. pubmed crossref bhaskaran k, dos-santos-silva i, leon da, et al. association of bmi with overall and cause-specific mortality: a population-based cohort study of 3.6 million adults in the uk. lancet diabetes endocrinol . 2018;6(12):944–953. pubmed crossref incerti d, jansen jp. hesim: health economic simulation modeling and decision analysis. 2021. doi :1 0.48550/arxiv.2102.09437 crossref attema ae, brouwer wbf, claxton k. discounting in economic evaluations. pharmacoeconomics . 2018;36(7):745–758. pubmed crossref carbon m, kane jm, leucht s, et al. tardive dyskinesia risk with first-and second-generation antipsychotics in comparative randomized controlled trials: a meta-analysis. world psychiatry . 2018;17(3):330–340. pubmed crossref morgenstern h, glazer wm. identifying risk factors for tardive dyskinesia among long-term outpatients maintained with neuroleptic medications: results of the yale tardive dyskinesia study. arch gen psychiatry . 1993;50(9):723–733. pubmed crossref woerner mg, alvir jmj, saltz bl, et al. prospective study of tardive dyskinesia in the elderly: rates and risk factors. aust j pharm . 1998;155(11):1521–1528. pubmed crossref tarsy d, lungu c, baldessarini rj. epidemiology of tardive dyskinesia before and during the era of modern antipsychotic drugs. handb clin neurol . 2011;100:601–616. pubmed crossref centers for disease control and prevention. web-based injury statistics query and reporting system (wisqars): cdc’s national center for injury prevention and control . 2002. accessed october 17, 2024. https://www.cdc.gov/injury/wisqars . tanner cm, caroff sn, cutler aj, et al. impact of possible tardive dyskinesia on physical wellness and social functioning: results from the real-world re-kinect study. j patient-rep outcomes . 2023;7(1):21. pubmed crossref ayyagari r, goldschmidt d, zhou m, et al. defining utility values for patients with tardive dyskinesia. curr med res opin . 2022;38(3):401–407. pubmed crossref mcevoy j, gandhi sk, rizio aa, et al. effect of tardive dyskinesia on quality of life in patients with bipolar disorder, major depressive disorder, and schizophrenia. qual life res . 2019;28(12):3303–3312. pubmed crossref judd ll, akiskal hs, maser jd, et al. a prospective 12-year study of subsyndromal and syndromal depressive symptoms in unipolar major depressive disorders. arch gen psychiatry . 1998;55(8):694–700. pubmed crossref mohiuddin s, payne k. utility values for adults with unipolar depression: systematic review and meta-analysis. med decis mak int j soc med decis mak . 2014;34(5):666–685. pubmed crossref revicki da, wood m. patient-assigned health state utilities for depression-related outcomes: differences by depression severity and antidepressant medications. j affect disord . 1998;48(1):25–36. pubmed crossref si l, winzenberg tm, de graaff b, palmer aj. a systematic review and meta-analysis of utility-based quality of life for osteoporosis-related conditions. osteoporos int j establ result coop eur found osteoporos natl osteoporos found usa . 2014;25(8):1987–1997. pubmed crossref ul-haq z, mackay df, fenwick e, pell jp. meta-analysis of the association between body mass index and health-related quality of life among adults, assessed by the sf-36. obes silver spring md . 2013;21(3):e322-e327 ross el, zivin k, maixner df. cost-effectiveness of electroconvulsive therapy vs pharmacotherapy/psychotherapy for treatment-resistant depression in the united states. jama psychiatry . 2018;75(7):713–722. pubmed crossref nuñez na, joseph b, pahwa m, et al. augmentation strategies for treatment resistant major depression: a systematic review and network meta-analysis. j affect disord . 2022;302:385–400. pubmed cheon ej, lee kh, park yw, et al. comparison of the efficacy and safety of aripiprazole versus bupropion augmentation in patients with major depressive disorder unresponsive to selective serotonin reuptake inhibitors: a randomized, prospective, open-label study. j clin psychopharmacol . 2017;37(2):193–199. pubmed crossref berman rm, thase me, trivedi mh, et al. long-term safety and tolerability of open-label aripiprazole augmentation of antidepressant therapy in major depressive disorder. neuropsychiatr dis treat . 2011;7:303–312. pubmed crossref barton bb, segger f, fischer k, et al. update on weight-gain caused by antipsychotics: a systematic review and meta-analysis. expert opin drug saf . 2020;19(3):295–314. pubmed crossref joo jh, lenze ej, mulsant bh, et al. risk factors for falls during treatment of late-life depression. j clin psychiatry . 2002;63(10):936–941. pubmed crossref jang sn, cho si, oh sw, et al. time since falling and fear of falling among community-dwelling elderly. int psychogeriatr . 2007;19(6):1072–1083. pubmed crossref katsoulis m, lai ag, diaz-ordaz k, et al. identifying adults at high-risk for change in weight and bmi in england: a longitudinal, large-scale, population-based cohort study using electronic health records. lancet diabetes endocrinol . 2021;9(10):681–694. pubmed crossref leucht s, cipriani a, spineli l, et al. comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. lancet . 2013;382(9896):951–962. pubmed crossref rhee tg, mohamed s, rosenheck ra. antipsychotic prescriptions among adults with major depressive disorder in office-based outpatient settings: national trends from 2006 to 2015. j clin psychiatry . 2018;79(2):17m11970. pubmed crossref gerhard t, akincigil a, correll cu, et al. national trends in second generation antipsychotic augmentation for non-psychotic depression. j clin psychiatry . 2014;75(5):490–497. pubmed crossref wang y, beydoun ma, min j, et al. has the prevalence of overweight, obesity and central obesity levelled off in the united states? trends, patterns, disparities, and future projections for the obesity epidemic. int j epidemiol . 2020;49(3):810–823. pubmed crossref luppino fs, de wit lm, bouvy pf, et al. overweight, obesity, and depression: a systematic review and meta-analysis of longitudinal studies. arch gen psychiatry . 2010;67(3):220–229. pubmed crossref fava m. lessons learned from the va augmentation and switching treatments for improving depression outcomes (vast-d) study. jama . 2017;318(2):126–128. pubmed crossref about the authors william u. meyerson, md, phd center for precision psychiatry, massachusetts general hospital, boston, massachusetts department of psychiatry, massachusetts general hospital/harvard medical school, boston, massachusetts corresponding author: william u. meyerson, md, phd, department of psychiatry, massachusetts general hospital/harvard medical school, simches research center, 185 cambridge st, boston, ma 02114 ( [email&#160;protected] ). view full profile eric l. ross, md department of psychiatry, larner college of medicine, university of vermont, burlington, vermont view full profile chris j. kennedy, phd, mpa center for precision psychiatry, massachusetts general hospital, boston, massachusetts department of psychiatry, massachusetts general hospital/harvard medical school, boston, massachusetts harvard medical school, boston, massachusetts view full profile rick h. hoyle, phd department of psychology and neuroscience, duke university, durham, north carolina view full profile jagpreet chhatwal, phd institute for technology assessment, massachusetts general hospital, harvard medical school, boston, massachusetts center for health decision science, harvard university, boston, massachusetts view full profile philip s. wang, md, drph division of pharmacoepidemiology and pharmacoeconomics, brigham and women’s hospital, harvard medical school, boston, massachusetts view full profile jordan w. smoller, md, scd center for precision psychiatry, massachusetts general hospital, boston, massachusetts department of psychiatry, massachusetts general hospital/harvard medical school, boston, massachusetts psychiatric and neurodevelopmental genetics unit, center for genomic medicine, massachusetts general hospital, boston, massachusetts view full profile buy pdf for $40 please sign in or purchase this pdf for $40. save share cite subscribe now already a member? login related news articles weekly mind reader: postpartum depression haunts one in six moms hair loss drug exacts a mental health toll decades in the making weekly mind reader: antidepressant use in pregnancy sponsored psychcase360: choosing the right long-acting injectable for patients with schizophrenia explore two real-world schizophrenia cases with roueen rafeyan, md and melissa vitale, pmhnp as they discuss challenges with medication adherence, transitioning to long-acting injectables (lais), and personalizing treatment strategies to improve patient outcomes. related jcp articles symptom network analysis of adhd and emotional symptoms in adults burnout in psychiatric doctors before and after the covid-19 pandemic effects of interpersonal and social rhythm therapy on suicidal ideation in adults with bipolar ii depression related pcc articles precision psychiatry for depression treatment predictors of depression response in a community ect clinic efficacy of glp-1 agonists in mental disorders vol 86 • 2025 • number 3 read the current issue original research treatment use and preference in a diverse sample of women with mood disorders original research klotho and matrix metalloproteinase-9 levels and their association with inhibitory dyscontrol in adolescents with first-episode major affective disorders original research niacin-induced response in early psychosis original research early ketamine response reduces suicidal events at 3 months letter to the editor suicide risk among patients with bipolar disorder: sleep disruption versus benzodiazepine use original research effect of nature videos on the burden of caregivers of patients with dementia view current issue related articles jcp original research association of immediate postpartum anxiety with postpartum depression october 15, 2025 the prevalence of immediate postpartum anxiety (ippa) in this population was 24%, and 7.4% for severe anxiety. among women with ippa, 31.2% developed postpartum depression. marie arnal , elodie-gaëlle ngameni , sarah tebeka , et al jcp original research depression at 2 months postpartum: results from the french national perinatal survey october 8, 2025 the prevalence of postpartum depression (ppd) at 2 months was 16.7%. factors associated with ppd included age ≤29 or ≥40 years, lower levels of health literacy, and a history... alexandra doncarli , virginie demiguel , camille le ray , et al jcp original research esmethadone (rel-1017) in patients with major depressive disorder and antidepressant tachyphylaxis october 6, 2025 esmethadone may be a potentially safe and effective adjunctive treatment for patients with mdd and antidepressant tachyphylaxis. clotilde guidetti , george i. papakostas , luca pani , et al expert consensus on aripiprazole lais in clinical practice read the full report subscribe to read more articles subscribe the journal of clinical psychiatry the primary care companion for cns disorders elsewhere: about advertisers media relations reprints & permissions contact us customer support follow us: x facebook instagram linkedin sign in join the email list subscribe now privacy policy terms of use physicians postgraduate press, inc. jcp issn: online 1555-2101, print 0160-6689 pcc issn: online 2155-7780, print 2155-7772 medfair.com us patent no. 684794 © copyright 2025 | physicians postgraduate press, inc. | lifelong learning for clinicians sitemap googletag.display("static-footer"); × // wait for klaviyo to load, then add custom properties document.addeventlistener('domcontentloaded', function() { // add custom properties to klaviyo tracking if (typeof klaviyo !== 'undefined') { // method a: set custom properties on the profile klaviyo.identify({ '$email': '', // add page-specific properties 'page_diseases': ["depression (mdd)"], 'primary_disease': "depression (mdd)", 'page_topics': ["depression (mdd)"], 'page_topics_count': 1, 'page_id': 220339, 'page_author': "tnq technologies", 'page_publish_date': "2025-09-22t04:00:33-05:00", 'journal': "jcp", 'last_page_view': '2025-10-21t06:06:30-05:00' }); // method b: track a custom event with page categories klaviyo.track('viewed content', { 'page_title': 'aripiprazole or bupropion augmentation versus switching to bupropion in treatment-resistant depression: a risk-benefit analysis', 'page_url': 'https://www.psychiatrist.com/jcp/aripiprazole-bupropion-augmentation-vs-switching-bupropion-treatment-resistant-depression-risk-benefit/', 'page_type': 'post', 'page_diseases': ["depression (mdd)"], 'primary_disease': "depression (mdd)", 'page_topics': ["depression (mdd)"], 'page_topics_count': 1, 'page_id': 220339, 'page_author': "tnq technologies", 'page_publish_date': "2025-09-22t04:00:33-05:00", 'journal': "jcp", 'timestamp': '2025-10-21t06:06:30-05:00' }); } }); (function () { var c = document.body.classname; c = c.replace(/woocommerce-no-js/, 'woocommerce-js'); document.body.classname = c; })(); var ajax = {"url":"https:\/\/www.psychiatrist.com\/wp-admin\/admin-ajax.php","nonce":"bee86d80ce","user":{"isloggedin":false,"user_type":"anon","membership_level":null,"subscribed_lists":[]},"klaviyo_lists":["sy2jg7","tkrrcd","qxiyyi","ufuy5l"]}; var wc_order_attribution = {"params":{"lifetime":1.0e-5,"session":30,"base64":false,"ajaxurl":"https:\/\/www.psychiatrist.com\/wp-admin\/admin-ajax.php","prefix":"wc_order_attribution_","allowtracking":true},"fields":{"source_type":"current.typ","referrer":"current_add.rf","utm_campaign":"current.cmp","utm_source":"current.src","utm_medium":"current.mdm","utm_content":"current.cnt","utm_id":"current.id","utm_term":"current.trm","utm_source_platform":"current.plt","utm_creative_format":"current.fmt","utm_marketing_tactic":"current.tct","session_entry":"current_add.ep","session_start_time":"current_add.fd","session_pages":"session.pgs","session_count":"udata.vst","user_agent":"udata.uag"}}; var kluser = {"current_user_email":"","commenter_email":""}; var psych_ajax = {"url":"https:\/\/www.psychiatrist.com\/wp-admin\/admin-ajax.php","nonce":"bee86d80ce","assets":{"spinner":"\/wp-content\/themes\/psych\/assets\/images\/spinner.gif","checkmark_white":"\/wp-content\/themes\/psych\/assets\/images\/icons\/check-white.svg","checkmark_tertiary":"\/wp-content\/themes\/psych\/assets\/images\/icons\/check-tertiary.svg","share":"\/wp-content\/themes\/psych\/assets\/images\/icons\/share.svg","quote":"\/wp-content\/themes\/psych\/assets\/images\/icons\/quote.svg","bookmark":"\/wp-content\/themes\/psych\/assets\/images\/icons\/bookmark-white.svg","bookmark_tertiary":"\/wp-content\/themes\/psych\/assets\/images\/icons\/bookmark-tertiary.svg"}}; var psych_ajax = {"url":"https:\/\/www.psychiatrist.com\/wp-admin\/admin-ajax.php","nonce":"bee86d80ce","assets":{"spinner":"\/wp-content\/themes\/psych\/assets\/images\/spinner.gif","checkmark_white":"\/wp-content\/themes\/psych\/assets\/images\/icons\/check-white.svg","checkmark_tertiary":"\/wp-content\/themes\/psych\/assets\/images\/icons\/check-tertiary.svg","share":"\/wp-content\/themes\/psych\/assets\/images\/icons\/share.svg","quote":"\/wp-content\/themes\/psych\/assets\/images\/icons\/quote.svg","bookmark":"\/wp-content\/themes\/psych\/assets\/images\/icons\/bookmark-white.svg","bookmark_tertiary":"\/wp-content\/themes\/psych\/assets\/images\/icons\/bookmark-tertiary.svg"}}; var ajax = {"url":"https:\/\/www.psychiatrist.com\/wp-admin\/admin-ajax.php","nonce":"bee86d80ce","user":{"isloggedin":false,"user_type":"anon","membership_level":null,"subscribed_lists":[]},"klaviyo_lists":["sy2jg7","tkrrcd","qxiyyi","ufuy5l"]}; var block = {"obj":"{\"terms\":[],\"dynamic_ads\":[{\"advertisement_gam_id\":\"sidebar-top\",\"ad_class\":\"gam-ad-slot\",\"mobile_hide_on\":true,\"mobile_max_width\":\"874\",\"div_id\":\"sidebar-top\",\"type\":\"square\",\"slot_targeting\":{\"position\":null,\"type\":\"square\"}}],\"config\":{\"ad-banner\":{\"type\":\"banner\",\"slug\":\"ad-banner\",\"sizes\":{\"small-banner\":{\"label\":\"small banner\",\"slug\":\"small-banner\",\"size\":{\"width\":320,\"height\":50}},\"medium-banner\":{\"label\":\"medium banner\",\"slug\":\"medium-banner\",\"size\":{\"width\":728,\"height\":90}}}},\"ad-square\":{\"type\":\"square\",\"slug\":\"ad-square\",\"sizes\":{\"square\":{\"label\":\"square\",\"slug\":\"square\",\"size\":{\"width\":300,\"height\":250}}}},\"ad-banner-square\":{\"type\":\"banner \\\/ square (mobile \\\/ desktop)\",\"slug\":\"ad-banner-square\",\"sizes\":{\"banner-square\":{\"label\":\"banner \\\/ square (mobile \\\/ desktop)\",\"slug\":\"banner-square\",\"size\":{\"width\":300,\"height\":250}}}},\"ad-rectangle\":{\"type\":\"rectangle\",\"slug\":\"ad-rectangle\",\"sizes\":{\"rectangle\":{\"label\":\"rectangle\",\"slug\":\"rectangle\",\"size\":{\"width\":300,\"height\":600}}}}},\"page_targeting\":{\"page_name\":\"aripiprazole or bupropion augmentation versus switching to bupropion in treatment-resistant depression: a risk-benefit analysis\",\"site_section\":\"academic_article\",\"post_type\":\"post\",\"post_id\":220339,\"permalink\":\"https:\\\/\\\/www.psychiatrist.com\\\/jcp\\\/aripiprazole-bupropion-augmentation-vs-switching-bupropion-treatment-resistant-depression-risk-benefit\\\/\",\"categories\":[\"depression\",\"early-career-psychiatrists\",\"original-research\"],\"journal\":\"jcp\"},\"page_ads\":[]}"}; var ajax = {"url":"https:\/\/www.psychiatrist.com\/wp-admin\/admin-ajax.php","nonce":"bee86d80ce","user":{"isloggedin":false,"user_type":"anon","membership_level":null,"subscribed_lists":[]},"klaviyo_lists":["sy2jg7","tkrrcd","qxiyyi","ufuy5l"]}; var block = {"obj":"{\"terms\":[],\"dynamic_ads\":[{\"advertisement_gam_id\":\"sidebar-top\",\"ad_class\":\"gam-ad-slot\",\"mobile_hide_on\":true,\"mobile_max_width\":\"874\",\"div_id\":\"sidebar-top\",\"type\":\"square\",\"slot_targeting\":{\"position\":null,\"type\":\"square\"}},{\"advertisement_gam_id\":\"sidebar-bottom\",\"ad_class\":\"gam-ad-slot\",\"mobile_hide_on\":true,\"mobile_max_width\":\"874\",\"div_id\":\"sidebar-bottom\",\"type\":\"square\",\"slot_targeting\":{\"position\":null,\"type\":\"square\"}}],\"config\":{\"ad-banner\":{\"type\":\"banner\",\"slug\":\"ad-banner\",\"sizes\":{\"small-banner\":{\"label\":\"small banner\",\"slug\":\"small-banner\",\"size\":{\"width\":320,\"height\":50}},\"medium-banner\":{\"label\":\"medium banner\",\"slug\":\"medium-banner\",\"size\":{\"width\":728,\"height\":90}}}},\"ad-square\":{\"type\":\"square\",\"slug\":\"ad-square\",\"sizes\":{\"square\":{\"label\":\"square\",\"slug\":\"square\",\"size\":{\"width\":300,\"height\":250}}}},\"ad-banner-square\":{\"type\":\"banner \\\/ square (mobile \\\/ desktop)\",\"slug\":\"ad-banner-square\",\"sizes\":{\"banner-square\":{\"label\":\"banner \\\/ square (mobile \\\/ desktop)\",\"slug\":\"banner-square\",\"size\":{\"width\":300,\"height\":250}}}},\"ad-rectangle\":{\"type\":\"rectangle\",\"slug\":\"ad-rectangle\",\"sizes\":{\"rectangle\":{\"label\":\"rectangle\",\"slug\":\"rectangle\",\"size\":{\"width\":300,\"height\":600}}}}},\"page_targeting\":{\"page_name\":\"aripiprazole or bupropion augmentation versus switching to bupropion in treatment-resistant depression: a risk-benefit analysis\",\"site_section\":\"academic_article\",\"post_type\":\"post\",\"post_id\":220339,\"permalink\":\"https:\\\/\\\/www.psychiatrist.com\\\/jcp\\\/aripiprazole-bupropion-augmentation-vs-switching-bupropion-treatment-resistant-depression-risk-benefit\\\/\",\"categories\":[\"depression\",\"early-career-psychiatrists\",\"original-research\"],\"journal\":\"jcp\"},\"page_ads\":[]}"}; window.usercontext = { isloggedin: false, hasemail: false, usertype: '' }; (function(){function c(){var b=a.contentdocument||a.contentwindow.document;if(b){var d=b.createelement('script');d.innerhtml="window.__cf$cv$params={r:'9920492c3c370384',t:'mtc2mta0ndc4oq=='};var a=document.createelement('script');a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getelementsbytagname('head')[0].appendchild(a);";b.getelementsbytagname('head')[0].appendchild(d)}}if(document.body){var a=document.createelement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendchild(a);if('loading'!==document.readystate)c();else if(window.addeventlistener)document.addeventlistener('domcontentloaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readystate&&(document.onreadystatechange=e,c())}}}})();

## Methods
results discussion article information clinical points the journal of clinical psychiatry depression (mdd) original research early career psychiatrists september 22, 2025 aripiprazole or bupropion augmentation versus switching to bupropion in treatment-resistant depression: a risk-benefit analysis william u. meyerson, md, phd ; eric l. ross, md ; chris j. kennedy, phd, mpa ; rick h. hoyle, phd ; jagpreet chhatwal, phd ; philip s. wang, md, drph ; jordan w. smoller, md, scd j clin psychiatry 2025;86(4):25m15863 abstract objective: in treatment-resistant depression (trd), augmentation with aripiprazole (a-ari) or combination therapy by adding bupropion (c-bup) has been reported as more effective than switching to bupropion (s-bup), but c-bup risks falls in older adults, and a-ari risks weight gain and tardive dyskinesia (td). the aim of this study was to clarify whether the enhanced effectiveness outweighs such risks. methods: in this risk-benefit decision analysis, lifetime quality-adjusted life-years (qalys) following 1 year of a-ari or c-bup vs s-bup treatment were simulated in a health-state transition model tracking depression remission, falls, weight gain, and td, in age and baseline body mass index (bmi) subgroups, using data from the vast-d and optimum trials and other literature. qalys were converted to depression-free day-equivalents (dfds), the qalys gained from 1 day of remitted versus active depression. results: simulated adults aged 18–64 years experienced a net benefit of c-bup over s-bup of 20.7 dfds, equivalent to about 3 weeks of faster remission of depressive symptoms. in older adults, especially those aged 85+ years, this benefit over s-bup was partially but not fully offset by a risk of falls. in adults aged 18–64 years, a-ari was estimated to offer only 8.0 dfds after subtracting the expected harms from td, and this was further reduced to −22.8 dfds once metabolic harms were considered, in those overweight at baseline. overall, c-bup was preferred over a-ari in all subgroups except ages 85–89 years with bmi&lt;25, in whom a-ari was preferred. conclusion: in our model, c-bup better balanced efficacy and tolerability in trd in adults under 85 years than did s-bup or a-ari. a-ari was least-preferred in overweight adults. these results may inform shared decision-making and clinical guidelines. j clin psychiatry 2025;86(4):25m15863 author affiliations are listed at the end of this article. members only content this full article is available exclusively to professional tier members. subscribe now to unlock the html version and gain unlimited access to our entire library plus all pdfs. if you’re already a subscriber, please log in below to continue reading. subscribe now already a member? log in references (52) gaynes bn, lux l, gartlehner g, et al. defining treatment-resistant depression. depress anxiety . 2020;37(2):134–145. pubmed crossref zhdanava m, pilon d, ghelerter i, et al. the prevalence and national burden of treatment-resistant depression and major depressive disorder in the united states. j clin psychiatry . 2021;82(2):20m13699. pubmed crossref hantouche e, angst j, azorin jm. explained factors of suicide attempts in major depression. j affect disord . 2010;127(1-3):305–308. pubmed crossref dunner dl, rush aj, russell jm, et al. prospective, long-term, multicenter study of the naturalistic outcomes of patients with treatment-resistant depression. j clin psychiatry . 2006;67(5):688–695. pubmed crossref fekadu a, wooderson sc, markopoulo k, et al. what happens to patients with treatment-resistant depression? a systematic review of medium to long term outcome studies. j affect disord . 2009;116(1–2):4–11. pubmed crossref johnston km, powell lc, anderson im, et al. the burden of treatment-resistant depression: a systematic review of the economic and quality of life literature. j affect disord . 2019;242:195–210. pubmed crossref the national institute for health and care excellence. depression in adults: treatment and management. nice; 2022. https://www.nice.org.uk/guidance/ accessed september 30, 2024. gelenberg aj, freeman mp, markowitz jc, et al. american psychiatric association practice guideline for the treatment of patients with major depressive disorder, third edition. am j psychiatry . 2010;167(suppl):1–152. pubmed mcquaid jr, buelt a, capaldi v, et al. the management of major depressive disorder: synopsis of the 2022 u.s. department of veterans affairs and u.s. department of defense clinical practice guideline. ann intern med . 2022;175(10):1440–1451. pubmed crossref mohamed s, johnson gr, chen p, et al. effect of antidepressant switching vs augmentation on remission among patients with major depressive disorder unresponsive to antidepressant treatment: the vast-d randomized clinical trial. jama . 2017;318(2):132–145. pubmed crossref lenze ej, mulsant bh, roose sp, et al. antidepressant augmentation versus switch in treatment-resistant geriatric depression. n engl j med . 2023;388(12):1067–1079. pubmed crossref kenny ra, romero-ortuno r, kumar p. falls in older adults. medicine . 2017;45(1):28–33. haslam dw, james wpt. obesity. lancet . 2005;366(9492):1197–1209. pubmed crossref speyer h, westergaard c, albert n, et al. reversibility of antipsychotic-induced weight gain: a systematic review and meta-analysis. front endocrinol . 2021;12:577919. pubmed crossref kiriakakis v, bhatia kp, quinn np, et al. the natural history of tardive dystonia. a long-term follow-up study of 107 cases. brain . 1998;121(11):2053–2066. pubmed caroff sn, yeomans k, lenderking wr, et al. re-kinect: a prospective study of the presence and healthcare burden of tardive dyskinesia in clinical practice settings. j clin psychopharmacol . 2020;40(3):259–268. pubmed crossref yoon j, zisook s, park a, et al. comparing cost-effectiveness of aripiprazole augmentation with other “next-step” depression treatment strategies: a randomized clinical trial. j clin psychiatry . 2018;80(1):18m12294. pubmed crossref garrison lp, towse a, bresnahan bw. assessing a structured, quantitative health outcomes approach to drug risk-benefit analysis. health aff . 2007;26(3):684–695. pubmed crossref ramani sv, richard a. decision, irreversibility and flexibility: the irreversibility effect re-examined. theor decis . 1993;35(3):259–276. crossref husereau d, drummond m, augustovski f, et al. consolidated health economic evaluation reporting standards 2022 (cheers 2022) statement: updated reporting guidance for health economic evaluations . society for medical decision making; 2022. https://journals.sagepub.com/doi/full/10.1177/ accessed october 17, 2024 meyerson w, ross e, kennedy c, et al. appendix for aripiprazole or bupropion augmentation vs switching to bupropion in treatment resistant depression. 2025. https://osf.io/6czyp/ . accessed may 16, 2025 zisook s, johnson gr, hicks p, et al. continuation phase treatment outcomes for switching, combining, or augmenting strategies for treatment-resistant major depressive disorder: a vast-d report. depress anxiety . 2021;38(2):185–195. pubmed crossref bhaskaran k, dos-santos-silva i, leon da, et al. association of bmi with overall and cause-specific mortality: a population-based cohort study of 3.6 million adults in the uk. lancet diabetes endocrinol . 2018;6(12):944–953. pubmed crossref incerti d, jansen jp. hesim: health economic simulation modeling and decision analysis. 2021. doi :1 0.48550/arxiv.2102.09437 crossref attema ae, brouwer wbf, claxton k. discounting in economic evaluations. pharmacoeconomics . 2018;36(7):745–758. pubmed crossref carbon m, kane jm, leucht s, et al. tardive dyskinesia risk with first-and second-generation antipsychotics in comparative randomized controlled trials: a meta-analysis. world psychiatry . 2018;17(3):330–340. pubmed crossref morgenstern h, glazer wm. identifying risk factors for tardive dyskinesia among long-term outpatients maintained with neuroleptic medications: results of the yale tardive dyskinesia study. arch gen psychiatry . 1993;50(9):723–733. pubmed crossref woerner mg, alvir jmj, saltz bl, et al. prospective study of tardive dyskinesia in the elderly: rates and risk factors. aust j pharm . 1998;155(11):1521–1528. pubmed crossref tarsy d, lungu c, baldessarini rj. epidemiology of tardive dyskinesia before and during the era of modern antipsychotic drugs. handb clin neurol . 2011;100:601–616. pubmed crossref centers for disease control and prevention. web-based injury statistics query and reporting system (wisqars): cdc’s national center for injury prevention and control . 2002. accessed october 17, 2024. https://www.cdc.gov/injury/wisqars . tanner cm, caroff sn, cutler aj, et al. impact of possible tardive dyskinesia on physical wellness and social functioning: results from the real-world re-kinect study. j patient-rep outcomes . 2023;7(1):21. pubmed crossref ayyagari r, goldschmidt d, zhou m, et al. defining utility values for patients with tardive dyskinesia. curr med res opin . 2022;38(3):401–407. pubmed crossref mcevoy j, gandhi sk, rizio aa, et al. effect of tardive dyskinesia on quality of life in patients with bipolar disorder, major depressive disorder, and schizophrenia. qual life res . 2019;28(12):3303–3312. pubmed crossref judd ll, akiskal hs, maser jd, et al. a prospective 12-year study of subsyndromal and syndromal depressive symptoms in unipolar major depressive disorders. arch gen psychiatry . 1998;55(8):694–700. pubmed crossref mohiuddin s, payne k. utility values for adults with unipolar depression: systematic review and meta-analysis. med decis mak int j soc med decis mak . 2014;34(5):666–685. pubmed crossref revicki da, wood m. patient-assigned health state utilities for depression-related outcomes: differences by depression severity and antidepressant medications. j affect disord . 1998;48(1):25–36. pubmed crossref si l, winzenberg tm, de graaff b, palmer aj. a systematic review and meta-analysis of utility-based quality of life for osteoporosis-related conditions. osteoporos int j establ result coop eur found osteoporos natl osteoporos found usa . 2014;25(8):1987–1997. pubmed crossref ul-haq z, mackay df, fenwick e, pell jp. meta-analysis of the association between body mass index and health-related quality of life among adults, assessed by the sf-36. obes silver spring md . 2013;21(3):e322-e327 ross el, zivin k, maixner df. cost-effectiveness of electroconvulsive therapy vs pharmacotherapy/psychotherapy for treatment-resistant depression in the united states. jama psychiatry . 2018;75(7):713–722. pubmed crossref nuñez na, joseph b, pahwa m, et al. augmentation strategies for treatment resistant major depression: a systematic review and network meta-analysis. j affect disord . 2022;302:385–400. pubmed cheon ej, lee kh, park yw, et al. comparison of the efficacy and safety of aripiprazole versus bupropion augmentation in patients with major depressive disorder unresponsive to selective serotonin reuptake inhibitors: a randomized, prospective, open-label study. j clin psychopharmacol . 2017;37(2):193–199. pubmed crossref berman rm, thase me, trivedi mh, et al. long-term safety and tolerability of open-label aripiprazole augmentation of antidepressant therapy in major depressive disorder. neuropsychiatr dis treat . 2011;7:303–312. pubmed crossref barton bb, segger f, fischer k, et al. update on weight-gain caused by antipsychotics: a systematic review and meta-analysis. expert opin drug saf . 2020;19(3):295–314. pubmed crossref joo jh, lenze ej, mulsant bh, et al. risk factors for falls during treatment of late-life depression. j clin psychiatry . 2002;63(10):936–941. pubmed crossref jang sn, cho si, oh sw, et al. time since falling and fear of falling among community-dwelling elderly. int psychogeriatr . 2007;19(6):1072–1083. pubmed crossref katsoulis m, lai ag, diaz-ordaz k, et al. identifying adults at high-risk for change in weight and bmi in england: a longitudinal, large-scale, population-based cohort study using electronic health records. lancet diabetes endocrinol . 2021;9(10):681–694. pubmed crossref leucht s, cipriani a, spineli l, et al. comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. lancet . 2013;382(9896):951–962. pubmed crossref rhee tg, mohamed s, rosenheck ra. antipsychotic prescriptions among adults with major depressive disorder in office-based outpatient settings: national trends from 2006 to 2015. j clin psychiatry . 2018;79(2):17m11970. pubmed crossref gerhard t, akincigil a, correll cu, et al. national trends in second generation antipsychotic augmentation for non-psychotic depression. j clin psychiatry . 2014;75(5):490–497. pubmed crossref wang y, beydoun ma, min j, et al. has the prevalence of overweight, obesity and central obesity levelled off in the united states? trends, patterns, disparities, and future projections for the obesity epidemic. int j epidemiol . 2020;49(3):810–823. pubmed crossref luppino fs, de wit lm, bouvy pf, et al. overweight, obesity, and depression: a systematic review and meta-analysis of longitudinal studies. arch gen psychiatry . 2010;67(3):220–229. pubmed crossref fava m. lessons learned from the va augmentation and switching treatments for improving depression outcomes (vast-d) study. jama . 2017;318(2):126–128. pubmed crossref about the authors william u. meyerson, md, phd center for precision psychiatry, massachusetts general hospital, boston, massachusetts department of psychiatry, massachusetts general hospital/harvard medical school, boston, massachusetts corresponding author: william u. meyerson, md, phd, department of psychiatry, massachusetts general hospital/harvard medical school, simches research center, 185 cambridge st, boston, ma 02114 ( [email&#160;protected] ). view full profile eric l. ross, md department of psychiatry, larner college of medicine, university of vermont, burlington, vermont view full profile chris j. kennedy, phd, mpa center for precision psychiatry, massachusetts general hospital, boston, massachusetts department of psychiatry, massachusetts general hospital/harvard medical school, boston, massachusetts harvard medical school, boston, massachusetts view full profile rick h. hoyle, phd department of psychology and neuroscience, duke university, durham, north carolina view full profile jagpreet chhatwal, phd institute for technology assessment, massachusetts general hospital, harvard medical school, boston, massachusetts center for health decision science, harvard university, boston, massachusetts view full profile philip s. wang, md, drph division of pharmacoepidemiology and pharmacoeconomics, brigham and women’s hospital, harvard medical school, boston, massachusetts view full profile jordan w. smoller, md, scd center for precision psychiatry, massachusetts general hospital, boston, massachusetts department of psychiatry, massachusetts general hospital/harvard medical school, boston, massachusetts psychiatric and neurodevelopmental genetics unit, center for genomic medicine, massachusetts general hospital, boston, massachusetts view full profile buy pdf for $40 please sign in or purchase this pdf for $40. save share cite subscribe now already a member? login related news articles weekly mind reader: postpartum depression haunts one in six moms hair loss drug exacts a mental health toll decades in the making weekly mind reader: antidepressant use in pregnancy sponsored psychcase360: choosing the right long-acting injectable for patients with schizophrenia explore two real-world schizophrenia cases with roueen rafeyan, md and melissa vitale, pmhnp as they discuss challenges with medication adherence, transitioning to long-acting injectables (lais), and personalizing treatment strategies to improve patient outcomes. related jcp articles symptom network analysis of adhd and emotional symptoms in adults burnout in psychiatric doctors before and after the covid-19 pandemic effects of interpersonal and social rhythm therapy on suicidal ideation in adults with bipolar ii depression related pcc articles precision psychiatry for depression treatment predictors of depression response in a community ect clinic efficacy of glp-1 agonists in mental disorders vol 86 • 2025 • number 3 read the current issue original research treatment use and preference in a diverse sample of women with mood disorders original research klotho and matrix metalloproteinase-9 levels and their association with inhibitory dyscontrol in adolescents with first-episode major affective disorders original research niacin-induced response in early psychosis original research early ketamine response reduces suicidal events at 3 months letter to the editor suicide risk among patients with bipolar disorder: sleep disruption versus benzodiazepine use original research effect of nature videos on the burden of caregivers of patients with dementia view current issue related articles jcp original research association of immediate postpartum anxiety with postpartum depression october 15, 2025 the prevalence of immediate postpartum anxiety (ippa) in this population was 24%, and 7.4% for severe anxiety. among women with ippa, 31.2% developed postpartum depression. marie arnal , elodie-gaëlle ngameni , sarah tebeka , et al jcp original research depression at 2 months postpartum: results from the french national perinatal survey october 8, 2025 the prevalence of postpartum depression (ppd) at 2 months was 16.7%. factors associated with ppd included age ≤29 or ≥40 years, lower levels of health literacy, and a history... alexandra doncarli , virginie demiguel , camille le ray , et al jcp original research esmethadone (rel-1017) in patients with major depressive disorder and antidepressant tachyphylaxis october 6, 2025 esmethadone may be a potentially safe and effective adjunctive treatment for patients with mdd and antidepressant tachyphylaxis. clotilde guidetti , george i. papakostas , luca pani , et al expert consensus on aripiprazole lais in clinical practice read the full report subscribe to read more articles subscribe the journal of clinical psychiatry the primary care companion for cns disorders elsewhere: about advertisers media relations reprints & permissions contact us customer support follow us: x facebook instagram linkedin sign in join the email list subscribe now privacy policy terms of use physicians postgraduate press, inc. jcp issn: online 1555-2101, print 0160-6689 pcc issn: online 2155-7780, print 2155-7772 medfair.com us patent no. 684794 © copyright 2025 | physicians postgraduate press, inc. | lifelong learning for clinicians sitemap googletag.display("static-footer"); × // wait for klaviyo to load, then add custom properties document.addeventlistener('domcontentloaded', function() { // add custom properties to klaviyo tracking if (typeof klaviyo !== 'undefined') { // method a: set custom properties on the profile klaviyo.identify({ '$email': '', // add page-specific properties 'page_diseases': ["depression (mdd)"], 'primary_disease': "depression (mdd)", 'page_topics': ["depression (mdd)"], 'page_topics_count': 1, 'page_id': 220339, 'page_author': "tnq technologies", 'page_publish_date': "2025-09-22t04:00:33-05:00", 'journal': "jcp", 'last_page_view': '2025-10-21t06:06:30-05:00' }); // method b: track a custom event with page categories klaviyo.track('viewed content', { 'page_title': 'aripiprazole or bupropion augmentation versus switching to bupropion in treatment-resistant depression: a risk-benefit analysis', 'page_url': 'https://www.psychiatrist.com/jcp/aripiprazole-bupropion-augmentation-vs-switching-bupropion-treatment-resistant-depression-risk-benefit/', 'page_type': 'post', 'page_diseases': ["depression (mdd)"], 'primary_disease': "depression (mdd)", 'page_topics': ["depression (mdd)"], 'page_topics_count': 1, 'page_id': 220339, 'page_author': "tnq technologies", 'page_publish_date': "2025-09-22t04:00:33-05:00", 'journal': "jcp", 'timestamp': '2025-10-21t06:06:30-05:00' }); } }); (function () { var c = document.body.classname; c = c.replace(/woocommerce-no-js/, 'woocommerce-js'); document.body.classname = c; })(); var ajax = {"url":"https:\/\/www.psychiatrist.com\/wp-admin\/admin-ajax.php","nonce":"bee86d80ce","user":{"isloggedin":false,"user_type":"anon","membership_level":null,"subscribed_lists":[]},"klaviyo_lists":["sy2jg7","tkrrcd","qxiyyi","ufuy5l"]}; var wc_order_attribution = {"params":{"lifetime":1.0e-5,"session":30,"base64":false,"ajaxurl":"https:\/\/www.psychiatrist.com\/wp-admin\/admin-ajax.php","prefix":"wc_order_attribution_","allowtracking":true},"fields":{"source_type":"current.typ","referrer":"current_add.rf","utm_campaign":"current.cmp","utm_source":"current.src","utm_medium":"current.mdm","utm_content":"current.cnt","utm_id":"current.id","utm_term":"current.trm","utm_source_platform":"current.plt","utm_creative_format":"current.fmt","utm_marketing_tactic":"current.tct","session_entry":"current_add.ep","session_start_time":"current_add.fd","session_pages":"session.pgs","session_count":"udata.vst","user_agent":"udata.uag"}}; var kluser = {"current_user_email":"","commenter_email":""}; var psych_ajax = {"url":"https:\/\/www.psychiatrist.com\/wp-admin\/admin-ajax.php","nonce":"bee86d80ce","assets":{"spinner":"\/wp-content\/themes\/psych\/assets\/images\/spinner.gif","checkmark_white":"\/wp-content\/themes\/psych\/assets\/images\/icons\/check-white.svg","checkmark_tertiary":"\/wp-content\/themes\/psych\/assets\/images\/icons\/check-tertiary.svg","share":"\/wp-content\/themes\/psych\/assets\/images\/icons\/share.svg","quote":"\/wp-content\/themes\/psych\/assets\/images\/icons\/quote.svg","bookmark":"\/wp-content\/themes\/psych\/assets\/images\/icons\/bookmark-white.svg","bookmark_tertiary":"\/wp-content\/themes\/psych\/assets\/images\/icons\/bookmark-tertiary.svg"}}; var psych_ajax = {"url":"https:\/\/www.psychiatrist.com\/wp-admin\/admin-ajax.php","nonce":"bee86d80ce","assets":{"spinner":"\/wp-content\/themes\/psych\/assets\/images\/spinner.gif","checkmark_white":"\/wp-content\/themes\/psych\/assets\/images\/icons\/check-white.svg","checkmark_tertiary":"\/wp-content\/themes\/psych\/assets\/images\/icons\/check-tertiary.svg","share":"\/wp-content\/themes\/psych\/assets\/images\/icons\/share.svg","quote":"\/wp-content\/themes\/psych\/assets\/images\/icons\/quote.svg","bookmark":"\/wp-content\/themes\/psych\/assets\/images\/icons\/bookmark-white.svg","bookmark_tertiary":"\/wp-content\/themes\/psych\/assets\/images\/icons\/bookmark-tertiary.svg"}}; var ajax = {"url":"https:\/\/www.psychiatrist.com\/wp-admin\/admin-ajax.php","nonce":"bee86d80ce","user":{"isloggedin":false,"user_type":"anon","membership_level":null,"subscribed_lists":[]},"klaviyo_lists":["sy2jg7","tkrrcd","qxiyyi","ufuy5l"]}; var block = {"obj":"{\"terms\":[],\"dynamic_ads\":[{\"advertisement_gam_id\":\"sidebar-top\",\"ad_class\":\"gam-ad-slot\",\"mobile_hide_on\":true,\"mobile_max_width\":\"874\",\"div_id\":\"sidebar-top\",\"type\":\"square\",\"slot_targeting\":{\"position\":null,\"type\":\"square\"}}],\"config\":{\"ad-banner\":{\"type\":\"banner\",\"slug\":\"ad-banner\",\"sizes\":{\"small-banner\":{\"label\":\"small banner\",\"slug\":\"small-banner\",\"size\":{\"width\":320,\"height\":50}},\"medium-banner\":{\"label\":\"medium banner\",\"slug\":\"medium-banner\",\"size\":{\"width\":728,\"height\":90}}}},\"ad-square\":{\"type\":\"square\",\"slug\":\"ad-square\",\"sizes\":{\"square\":{\"label\":\"square\",\"slug\":\"square\",\"size\":{\"width\":300,\"height\":250}}}},\"ad-banner-square\":{\"type\":\"banner \\\/ square (mobile \\\/ desktop)\",\"slug\":\"ad-banner-square\",\"sizes\":{\"banner-square\":{\"label\":\"banner \\\/ square (mobile \\\/ desktop)\",\"slug\":\"banner-square\",\"size\":{\"width\":300,\"height\":250}}}},\"ad-rectangle\":{\"type\":\"rectangle\",\"slug\":\"ad-rectangle\",\"sizes\":{\"rectangle\":{\"label\":\"rectangle\",\"slug\":\"rectangle\",\"size\":{\"width\":300,\"height\":600}}}}},\"page_targeting\":{\"page_name\":\"aripiprazole or bupropion augmentation versus switching to bupropion in treatment-resistant depression: a risk-benefit analysis\",\"site_section\":\"academic_article\",\"post_type\":\"post\",\"post_id\":220339,\"permalink\":\"https:\\\/\\\/www.psychiatrist.com\\\/jcp\\\/aripiprazole-bupropion-augmentation-vs-switching-bupropion-treatment-resistant-depression-risk-benefit\\\/\",\"categories\":[\"depression\",\"early-career-psychiatrists\",\"original-research\"],\"journal\":\"jcp\"},\"page_ads\":[]}"}; var ajax = {"url":"https:\/\/www.psychiatrist.com\/wp-admin\/admin-ajax.php","nonce":"bee86d80ce","user":{"isloggedin":false,"user_type":"anon","membership_level":null,"subscribed_lists":[]},"klaviyo_lists":["sy2jg7","tkrrcd","qxiyyi","ufuy5l"]}; var block = {"obj":"{\"terms\":[],\"dynamic_ads\":[{\"advertisement_gam_id\":\"sidebar-top\",\"ad_class\":\"gam-ad-slot\",\"mobile_hide_on\":true,\"mobile_max_width\":\"874\",\"div_id\":\"sidebar-top\",\"type\":\"square\",\"slot_targeting\":{\"position\":null,\"type\":\"square\"}},{\"advertisement_gam_id\":\"sidebar-bottom\",\"ad_class\":\"gam-ad-slot\",\"mobile_hide_on\":true,\"mobile_max_width\":\"874\",\"div_id\":\"sidebar-bottom\",\"type\":\"square\",\"slot_targeting\":{\"position\":null,\"type\":\"square\"}}],\"config\":{\"ad-banner\":{\"type\":\"banner\",\"slug\":\"ad-banner\",\"sizes\":{\"small-banner\":{\"label\":\"small banner\",\"slug\":\"small-banner\",\"size\":{\"width\":320,\"height\":50}},\"medium-banner\":{\"label\":\"medium banner\",\"slug\":\"medium-banner\",\"size\":{\"width\":728,\"height\":90}}}},\"ad-square\":{\"type\":\"square\",\"slug\":\"ad-square\",\"sizes\":{\"square\":{\"label\":\"square\",\"slug\":\"square\",\"size\":{\"width\":300,\"height\":250}}}},\"ad-banner-square\":{\"type\":\"banner \\\/ square (mobile \\\/ desktop)\",\"slug\":\"ad-banner-square\",\"sizes\":{\"banner-square\":{\"label\":\"banner \\\/ square (mobile \\\/ desktop)\",\"slug\":\"banner-square\",\"size\":{\"width\":300,\"height\":250}}}},\"ad-rectangle\":{\"type\":\"rectangle\",\"slug\":\"ad-rectangle\",\"sizes\":{\"rectangle\":{\"label\":\"rectangle\",\"slug\":\"rectangle\",\"size\":{\"width\":300,\"height\":600}}}}},\"page_targeting\":{\"page_name\":\"aripiprazole or bupropion augmentation versus switching to bupropion in treatment-resistant depression: a risk-benefit analysis\",\"site_section\":\"academic_article\",\"post_type\":\"post\",\"post_id\":220339,\"permalink\":\"https:\\\/\\\/www.psychiatrist.com\\\/jcp\\\/aripiprazole-bupropion-augmentation-vs-switching-bupropion-treatment-resistant-depression-risk-benefit\\\/\",\"categories\":[\"depression\",\"early-career-psychiatrists\",\"original-research\"],\"journal\":\"jcp\"},\"page_ads\":[]}"}; window.usercontext = { isloggedin: false, hasemail: false, usertype: '' }; (function(){function c(){var b=a.contentdocument||a.contentwindow.document;if(b){var d=b.createelement('script');d.innerhtml="window.__cf$cv$params={r:'9920492c3c370384',t:'mtc2mta0ndc4oq=='};var a=document.createelement('script');a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getelementsbytagname('head')[0].appendchild(a);";b.getelementsbytagname('head')[0].appendchild(d)}}if(document.body){var a=document.createelement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendchild(a);if('loading'!==document.readystate)c();else if(window.addeventlistener)document.addeventlistener('domcontentloaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readystate&&(document.onreadystatechange=e,c())}}}})();

## Results
discussion article information clinical points the journal of clinical psychiatry depression (mdd) original research early career psychiatrists september 22, 2025 aripiprazole or bupropion augmentation versus switching to bupropion in treatment-resistant depression: a risk-benefit analysis william u. meyerson, md, phd ; eric l. ross, md ; chris j. kennedy, phd, mpa ; rick h. hoyle, phd ; jagpreet chhatwal, phd ; philip s. wang, md, drph ; jordan w. smoller, md, scd j clin psychiatry 2025;86(4):25m15863 abstract objective: in treatment-resistant depression (trd), augmentation with aripiprazole (a-ari) or combination therapy by adding bupropion (c-bup) has been reported as more effective than switching to bupropion (s-bup), but c-bup risks falls in older adults, and a-ari risks weight gain and tardive dyskinesia (td). the aim of this study was to clarify whether the enhanced effectiveness outweighs such risks. methods: in this risk-benefit decision analysis, lifetime quality-adjusted life-years (qalys) following 1 year of a-ari or c-bup vs s-bup treatment were simulated in a health-state transition model tracking depression remission, falls, weight gain, and td, in age and baseline body mass index (bmi) subgroups, using data from the vast-d and optimum trials and other literature. qalys were converted to depression-free day-equivalents (dfds), the qalys gained from 1 day of remitted versus active depression. results: simulated adults aged 18–64 years experienced a net benefit of c-bup over s-bup of 20.7 dfds, equivalent to about 3 weeks of faster remission of depressive symptoms. in older adults, especially those aged 85+ years, this benefit over s-bup was partially but not fully offset by a risk of falls. in adults aged 18–64 years, a-ari was estimated to offer only 8.0 dfds after subtracting the expected harms from td, and this was further reduced to −22.8 dfds once metabolic harms were considered, in those overweight at baseline. overall, c-bup was preferred over a-ari in all subgroups except ages 85–89 years with bmi&lt;25, in whom a-ari was preferred. conclusion: in our model, c-bup better balanced efficacy and tolerability in trd in adults under 85 years than did s-bup or a-ari. a-ari was least-preferred in overweight adults. these results may inform shared decision-making and clinical guidelines. j clin psychiatry 2025;86(4):25m15863 author affiliations are listed at the end of this article. members only content this full article is available exclusively to professional tier members. subscribe now to unlock the html version and gain unlimited access to our entire library plus all pdfs. if you’re already a subscriber, please log in below to continue reading. subscribe now already a member? log in references (52) gaynes bn, lux l, gartlehner g, et al. defining treatment-resistant depression. depress anxiety . 2020;37(2):134–145. pubmed crossref zhdanava m, pilon d, ghelerter i, et al. the prevalence and national burden of treatment-resistant depression and major depressive disorder in the united states. j clin psychiatry . 2021;82(2):20m13699. pubmed crossref hantouche e, angst j, azorin jm. explained factors of suicide attempts in major depression. j affect disord . 2010;127(1-3):305–308. pubmed crossref dunner dl, rush aj, russell jm, et al. prospective, long-term, multicenter study of the naturalistic outcomes of patients with treatment-resistant depression. j clin psychiatry . 2006;67(5):688–695. pubmed crossref fekadu a, wooderson sc, markopoulo k, et al. what happens to patients with treatment-resistant depression? a systematic review of medium to long term outcome studies. j affect disord . 2009;116(1–2):4–11. pubmed crossref johnston km, powell lc, anderson im, et al. the burden of treatment-resistant depression: a systematic review of the economic and quality of life literature. j affect disord . 2019;242:195–210. pubmed crossref the national institute for health and care excellence. depression in adults: treatment and management. nice; 2022. https://www.nice.org.uk/guidance/ accessed september 30, 2024. gelenberg aj, freeman mp, markowitz jc, et al. american psychiatric association practice guideline for the treatment of patients with major depressive disorder, third edition. am j psychiatry . 2010;167(suppl):1–152. pubmed mcquaid jr, buelt a, capaldi v, et al. the management of major depressive disorder: synopsis of the 2022 u.s. department of veterans affairs and u.s. department of defense clinical practice guideline. ann intern med . 2022;175(10):1440–1451. pubmed crossref mohamed s, johnson gr, chen p, et al. effect of antidepressant switching vs augmentation on remission among patients with major depressive disorder unresponsive to antidepressant treatment: the vast-d randomized clinical trial. jama . 2017;318(2):132–145. pubmed crossref lenze ej, mulsant bh, roose sp, et al. antidepressant augmentation versus switch in treatment-resistant geriatric depression. n engl j med . 2023;388(12):1067–1079. pubmed crossref kenny ra, romero-ortuno r, kumar p. falls in older adults. medicine . 2017;45(1):28–33. haslam dw, james wpt. obesity. lancet . 2005;366(9492):1197–1209. pubmed crossref speyer h, westergaard c, albert n, et al. reversibility of antipsychotic-induced weight gain: a systematic review and meta-analysis. front endocrinol . 2021;12:577919. pubmed crossref kiriakakis v, bhatia kp, quinn np, et al. the natural history of tardive dystonia. a long-term follow-up study of 107 cases. brain . 1998;121(11):2053–2066. pubmed caroff sn, yeomans k, lenderking wr, et al. re-kinect: a prospective study of the presence and healthcare burden of tardive dyskinesia in clinical practice settings. j clin psychopharmacol . 2020;40(3):259–268. pubmed crossref yoon j, zisook s, park a, et al. comparing cost-effectiveness of aripiprazole augmentation with other “next-step” depression treatment strategies: a randomized clinical trial. j clin psychiatry . 2018;80(1):18m12294. pubmed crossref garrison lp, towse a, bresnahan bw. assessing a structured, quantitative health outcomes approach to drug risk-benefit analysis. health aff . 2007;26(3):684–695. pubmed crossref ramani sv, richard a. decision, irreversibility and flexibility: the irreversibility effect re-examined. theor decis . 1993;35(3):259–276. crossref husereau d, drummond m, augustovski f, et al. consolidated health economic evaluation reporting standards 2022 (cheers 2022) statement: updated reporting guidance for health economic evaluations . society for medical decision making; 2022. https://journals.sagepub.com/doi/full/10.1177/ accessed october 17, 2024 meyerson w, ross e, kennedy c, et al. appendix for aripiprazole or bupropion augmentation vs switching to bupropion in treatment resistant depression. 2025. https://osf.io/6czyp/ . accessed may 16, 2025 zisook s, johnson gr, hicks p, et al. continuation phase treatment outcomes for switching, combining, or augmenting strategies for treatment-resistant major depressive disorder: a vast-d report. depress anxiety . 2021;38(2):185–195. pubmed crossref bhaskaran k, dos-santos-silva i, leon da, et al. association of bmi with overall and cause-specific mortality: a population-based cohort study of 3.6 million adults in the uk. lancet diabetes endocrinol . 2018;6(12):944–953. pubmed crossref incerti d, jansen jp. hesim: health economic simulation modeling and decision analysis. 2021. doi :1 0.48550/arxiv.2102.09437 crossref attema ae, brouwer wbf, claxton k. discounting in economic evaluations. pharmacoeconomics . 2018;36(7):745–758. pubmed crossref carbon m, kane jm, leucht s, et al. tardive dyskinesia risk with first-and second-generation antipsychotics in comparative randomized controlled trials: a meta-analysis. world psychiatry . 2018;17(3):330–340. pubmed crossref morgenstern h, glazer wm. identifying risk factors for tardive dyskinesia among long-term outpatients maintained with neuroleptic medications: results of the yale tardive dyskinesia study. arch gen psychiatry . 1993;50(9):723–733. pubmed crossref woerner mg, alvir jmj, saltz bl, et al. prospective study of tardive dyskinesia in the elderly: rates and risk factors. aust j pharm . 1998;155(11):1521–1528. pubmed crossref tarsy d, lungu c, baldessarini rj. epidemiology of tardive dyskinesia before and during the era of modern antipsychotic drugs. handb clin neurol . 2011;100:601–616. pubmed crossref centers for disease control and prevention. web-based injury statistics query and reporting system (wisqars): cdc’s national center for injury prevention and control . 2002. accessed october 17, 2024. https://www.cdc.gov/injury/wisqars . tanner cm, caroff sn, cutler aj, et al. impact of possible tardive dyskinesia on physical wellness and social functioning: results from the real-world re-kinect study. j patient-rep outcomes . 2023;7(1):21. pubmed crossref ayyagari r, goldschmidt d, zhou m, et al. defining utility values for patients with tardive dyskinesia. curr med res opin . 2022;38(3):401–407. pubmed crossref mcevoy j, gandhi sk, rizio aa, et al. effect of tardive dyskinesia on quality of life in patients with bipolar disorder, major depressive disorder, and schizophrenia. qual life res . 2019;28(12):3303–3312. pubmed crossref judd ll, akiskal hs, maser jd, et al. a prospective 12-year study of subsyndromal and syndromal depressive symptoms in unipolar major depressive disorders. arch gen psychiatry . 1998;55(8):694–700. pubmed crossref mohiuddin s, payne k. utility values for adults with unipolar depression: systematic review and meta-analysis. med decis mak int j soc med decis mak . 2014;34(5):666–685. pubmed crossref revicki da, wood m. patient-assigned health state utilities for depression-related outcomes: differences by depression severity and antidepressant medications. j affect disord . 1998;48(1):25–36. pubmed crossref si l, winzenberg tm, de graaff b, palmer aj. a systematic review and meta-analysis of utility-based quality of life for osteoporosis-related conditions. osteoporos int j establ result coop eur found osteoporos natl osteoporos found usa . 2014;25(8):1987–1997. pubmed crossref ul-haq z, mackay df, fenwick e, pell jp. meta-analysis of the association between body mass index and health-related quality of life among adults, assessed by the sf-36. obes silver spring md . 2013;21(3):e322-e327 ross el, zivin k, maixner df. cost-effectiveness of electroconvulsive therapy vs pharmacotherapy/psychotherapy for treatment-resistant depression in the united states. jama psychiatry . 2018;75(7):713–722. pubmed crossref nuñez na, joseph b, pahwa m, et al. augmentation strategies for treatment resistant major depression: a systematic review and network meta-analysis. j affect disord . 2022;302:385–400. pubmed cheon ej, lee kh, park yw, et al. comparison of the efficacy and safety of aripiprazole versus bupropion augmentation in patients with major depressive disorder unresponsive to selective serotonin reuptake inhibitors: a randomized, prospective, open-label study. j clin psychopharmacol . 2017;37(2):193–199. pubmed crossref berman rm, thase me, trivedi mh, et al. long-term safety and tolerability of open-label aripiprazole augmentation of antidepressant therapy in major depressive disorder. neuropsychiatr dis treat . 2011;7:303–312. pubmed crossref barton bb, segger f, fischer k, et al. update on weight-gain caused by antipsychotics: a systematic review and meta-analysis. expert opin drug saf . 2020;19(3):295–314. pubmed crossref joo jh, lenze ej, mulsant bh, et al. risk factors for falls during treatment of late-life depression. j clin psychiatry . 2002;63(10):936–941. pubmed crossref jang sn, cho si, oh sw, et al. time since falling and fear of falling among community-dwelling elderly. int psychogeriatr . 2007;19(6):1072–1083. pubmed crossref katsoulis m, lai ag, diaz-ordaz k, et al. identifying adults at high-risk for change in weight and bmi in england: a longitudinal, large-scale, population-based cohort study using electronic health records. lancet diabetes endocrinol . 2021;9(10):681–694. pubmed crossref leucht s, cipriani a, spineli l, et al. comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. lancet . 2013;382(9896):951–962. pubmed crossref rhee tg, mohamed s, rosenheck ra. antipsychotic prescriptions among adults with major depressive disorder in office-based outpatient settings: national trends from 2006 to 2015. j clin psychiatry . 2018;79(2):17m11970. pubmed crossref gerhard t, akincigil a, correll cu, et al. national trends in second generation antipsychotic augmentation for non-psychotic depression. j clin psychiatry . 2014;75(5):490–497. pubmed crossref wang y, beydoun ma, min j, et al. has the prevalence of overweight, obesity and central obesity levelled off in the united states? trends, patterns, disparities, and future projections for the obesity epidemic. int j epidemiol . 2020;49(3):810–823. pubmed crossref luppino fs, de wit lm, bouvy pf, et al. overweight, obesity, and depression: a systematic review and meta-analysis of longitudinal studies. arch gen psychiatry . 2010;67(3):220–229. pubmed crossref fava m. lessons learned from the va augmentation and switching treatments for improving depression outcomes (vast-d) study. jama . 2017;318(2):126–128. pubmed crossref about the authors william u. meyerson, md, phd center for precision psychiatry, massachusetts general hospital, boston, massachusetts department of psychiatry, massachusetts general hospital/harvard medical school, boston, massachusetts corresponding author: william u. meyerson, md, phd, department of psychiatry, massachusetts general hospital/harvard medical school, simches research center, 185 cambridge st, boston, ma 02114 ( [email&#160;protected] ). view full profile eric l. ross, md department of psychiatry, larner college of medicine, university of vermont, burlington, vermont view full profile chris j. kennedy, phd, mpa center for precision psychiatry, massachusetts general hospital, boston, massachusetts department of psychiatry, massachusetts general hospital/harvard medical school, boston, massachusetts harvard medical school, boston, massachusetts view full profile rick h. hoyle, phd department of psychology and neuroscience, duke university, durham, north carolina view full profile jagpreet chhatwal, phd institute for technology assessment, massachusetts general hospital, harvard medical school, boston, massachusetts center for health decision science, harvard university, boston, massachusetts view full profile philip s. wang, md, drph division of pharmacoepidemiology and pharmacoeconomics, brigham and women’s hospital, harvard medical school, boston, massachusetts view full profile jordan w. smoller, md, scd center for precision psychiatry, massachusetts general hospital, boston, massachusetts department of psychiatry, massachusetts general hospital/harvard medical school, boston, massachusetts psychiatric and neurodevelopmental genetics unit, center for genomic medicine, massachusetts general hospital, boston, massachusetts view full profile buy pdf for $40 please sign in or purchase this pdf for $40. save share cite subscribe now already a member? login related news articles weekly mind reader: postpartum depression haunts one in six moms hair loss drug exacts a mental health toll decades in the making weekly mind reader: antidepressant use in pregnancy sponsored psychcase360: choosing the right long-acting injectable for patients with schizophrenia explore two real-world schizophrenia cases with roueen rafeyan, md and melissa vitale, pmhnp as they discuss challenges with medication adherence, transitioning to long-acting injectables (lais), and personalizing treatment strategies to improve patient outcomes. related jcp articles symptom network analysis of adhd and emotional symptoms in adults burnout in psychiatric doctors before and after the covid-19 pandemic effects of interpersonal and social rhythm therapy on suicidal ideation in adults with bipolar ii depression related pcc articles precision psychiatry for depression treatment predictors of depression response in a community ect clinic efficacy of glp-1 agonists in mental disorders vol 86 • 2025 • number 3 read the current issue original research treatment use and preference in a diverse sample of women with mood disorders original research klotho and matrix metalloproteinase-9 levels and their association with inhibitory dyscontrol in adolescents with first-episode major affective disorders original research niacin-induced response in early psychosis original research early ketamine response reduces suicidal events at 3 months letter to the editor suicide risk among patients with bipolar disorder: sleep disruption versus benzodiazepine use original research effect of nature videos on the burden of caregivers of patients with dementia view current issue related articles jcp original research association of immediate postpartum anxiety with postpartum depression october 15, 2025 the prevalence of immediate postpartum anxiety (ippa) in this population was 24%, and 7.4% for severe anxiety. among women with ippa, 31.2% developed postpartum depression. marie arnal , elodie-gaëlle ngameni , sarah tebeka , et al jcp original research depression at 2 months postpartum: results from the french national perinatal survey october 8, 2025 the prevalence of postpartum depression (ppd) at 2 months was 16.7%. factors associated with ppd included age ≤29 or ≥40 years, lower levels of health literacy, and a history... alexandra doncarli , virginie demiguel , camille le ray , et al jcp original research esmethadone (rel-1017) in patients with major depressive disorder and antidepressant tachyphylaxis october 6, 2025 esmethadone may be a potentially safe and effective adjunctive treatment for patients with mdd and antidepressant tachyphylaxis. clotilde guidetti , george i. papakostas , luca pani , et al expert consensus on aripiprazole lais in clinical practice read the full report subscribe to read more articles subscribe the journal of clinical psychiatry the primary care companion for cns disorders elsewhere: about advertisers media relations reprints & permissions contact us customer support follow us: x facebook instagram linkedin sign in join the email list subscribe now privacy policy terms of use physicians postgraduate press, inc. jcp issn: online 1555-2101, print 0160-6689 pcc issn: online 2155-7780, print 2155-7772 medfair.com us patent no. 684794 © copyright 2025 | physicians postgraduate press, inc. | lifelong learning for clinicians sitemap googletag.display("static-footer"); × // wait for klaviyo to load, then add custom properties document.addeventlistener('domcontentloaded', function() { // add custom properties to klaviyo tracking if (typeof klaviyo !== 'undefined') { // method a: set custom properties on the profile klaviyo.identify({ '$email': '', // add page-specific properties 'page_diseases': ["depression (mdd)"], 'primary_disease': "depression (mdd)", 'page_topics': ["depression (mdd)"], 'page_topics_count': 1, 'page_id': 220339, 'page_author': "tnq technologies", 'page_publish_date': "2025-09-22t04:00:33-05:00", 'journal': "jcp", 'last_page_view': '2025-10-21t06:06:30-05:00' }); // method b: track a custom event with page categories klaviyo.track('viewed content', { 'page_title': 'aripiprazole or bupropion augmentation versus switching to bupropion in treatment-resistant depression: a risk-benefit analysis', 'page_url': 'https://www.psychiatrist.com/jcp/aripiprazole-bupropion-augmentation-vs-switching-bupropion-treatment-resistant-depression-risk-benefit/', 'page_type': 'post', 'page_diseases': ["depression (mdd)"], 'primary_disease': "depression (mdd)", 'page_topics': ["depression (mdd)"], 'page_topics_count': 1, 'page_id': 220339, 'page_author': "tnq technologies", 'page_publish_date': "2025-09-22t04:00:33-05:00", 'journal': "jcp", 'timestamp': '2025-10-21t06:06:30-05:00' }); } }); (function () { var c = document.body.classname; c = c.replace(/woocommerce-no-js/, 'woocommerce-js'); document.body.classname = c; })(); var ajax = {"url":"https:\/\/www.psychiatrist.com\/wp-admin\/admin-ajax.php","nonce":"bee86d80ce","user":{"isloggedin":false,"user_type":"anon","membership_level":null,"subscribed_lists":[]},"klaviyo_lists":["sy2jg7","tkrrcd","qxiyyi","ufuy5l"]}; var wc_order_attribution = {"params":{"lifetime":1.0e-5,"session":30,"base64":false,"ajaxurl":"https:\/\/www.psychiatrist.com\/wp-admin\/admin-ajax.php","prefix":"wc_order_attribution_","allowtracking":true},"fields":{"source_type":"current.typ","referrer":"current_add.rf","utm_campaign":"current.cmp","utm_source":"current.src","utm_medium":"current.mdm","utm_content":"current.cnt","utm_id":"current.id","utm_term":"current.trm","utm_source_platform":"current.plt","utm_creative_format":"current.fmt","utm_marketing_tactic":"current.tct","session_entry":"current_add.ep","session_start_time":"current_add.fd","session_pages":"session.pgs","session_count":"udata.vst","user_agent":"udata.uag"}}; var kluser = {"current_user_email":"","commenter_email":""}; var psych_ajax = {"url":"https:\/\/www.psychiatrist.com\/wp-admin\/admin-ajax.php","nonce":"bee86d80ce","assets":{"spinner":"\/wp-content\/themes\/psych\/assets\/images\/spinner.gif","checkmark_white":"\/wp-content\/themes\/psych\/assets\/images\/icons\/check-white.svg","checkmark_tertiary":"\/wp-content\/themes\/psych\/assets\/images\/icons\/check-tertiary.svg","share":"\/wp-content\/themes\/psych\/assets\/images\/icons\/share.svg","quote":"\/wp-content\/themes\/psych\/assets\/images\/icons\/quote.svg","bookmark":"\/wp-content\/themes\/psych\/assets\/images\/icons\/bookmark-white.svg","bookmark_tertiary":"\/wp-content\/themes\/psych\/assets\/images\/icons\/bookmark-tertiary.svg"}}; var psych_ajax = {"url":"https:\/\/www.psychiatrist.com\/wp-admin\/admin-ajax.php","nonce":"bee86d80ce","assets":{"spinner":"\/wp-content\/themes\/psych\/assets\/images\/spinner.gif","checkmark_white":"\/wp-content\/themes\/psych\/assets\/images\/icons\/check-white.svg","checkmark_tertiary":"\/wp-content\/themes\/psych\/assets\/images\/icons\/check-tertiary.svg","share":"\/wp-content\/themes\/psych\/assets\/images\/icons\/share.svg","quote":"\/wp-content\/themes\/psych\/assets\/images\/icons\/quote.svg","bookmark":"\/wp-content\/themes\/psych\/assets\/images\/icons\/bookmark-white.svg","bookmark_tertiary":"\/wp-content\/themes\/psych\/assets\/images\/icons\/bookmark-tertiary.svg"}}; var ajax = {"url":"https:\/\/www.psychiatrist.com\/wp-admin\/admin-ajax.php","nonce":"bee86d80ce","user":{"isloggedin":false,"user_type":"anon","membership_level":null,"subscribed_lists":[]},"klaviyo_lists":["sy2jg7","tkrrcd","qxiyyi","ufuy5l"]}; var block = {"obj":"{\"terms\":[],\"dynamic_ads\":[{\"advertisement_gam_id\":\"sidebar-top\",\"ad_class\":\"gam-ad-slot\",\"mobile_hide_on\":true,\"mobile_max_width\":\"874\",\"div_id\":\"sidebar-top\",\"type\":\"square\",\"slot_targeting\":{\"position\":null,\"type\":\"square\"}}],\"config\":{\"ad-banner\":{\"type\":\"banner\",\"slug\":\"ad-banner\",\"sizes\":{\"small-banner\":{\"label\":\"small banner\",\"slug\":\"small-banner\",\"size\":{\"width\":320,\"height\":50}},\"medium-banner\":{\"label\":\"medium banner\",\"slug\":\"medium-banner\",\"size\":{\"width\":728,\"height\":90}}}},\"ad-square\":{\"type\":\"square\",\"slug\":\"ad-square\",\"sizes\":{\"square\":{\"label\":\"square\",\"slug\":\"square\",\"size\":{\"width\":300,\"height\":250}}}},\"ad-banner-square\":{\"type\":\"banner \\\/ square (mobile \\\/ desktop)\",\"slug\":\"ad-banner-square\",\"sizes\":{\"banner-square\":{\"label\":\"banner \\\/ square (mobile \\\/ desktop)\",\"slug\":\"banner-square\",\"size\":{\"width\":300,\"height\":250}}}},\"ad-rectangle\":{\"type\":\"rectangle\",\"slug\":\"ad-rectangle\",\"sizes\":{\"rectangle\":{\"label\":\"rectangle\",\"slug\":\"rectangle\",\"size\":{\"width\":300,\"height\":600}}}}},\"page_targeting\":{\"page_name\":\"aripiprazole or bupropion augmentation versus switching to bupropion in treatment-resistant depression: a risk-benefit analysis\",\"site_section\":\"academic_article\",\"post_type\":\"post\",\"post_id\":220339,\"permalink\":\"https:\\\/\\\/www.psychiatrist.com\\\/jcp\\\/aripiprazole-bupropion-augmentation-vs-switching-bupropion-treatment-resistant-depression-risk-benefit\\\/\",\"categories\":[\"depression\",\"early-career-psychiatrists\",\"original-research\"],\"journal\":\"jcp\"},\"page_ads\":[]}"}; var ajax = {"url":"https:\/\/www.psychiatrist.com\/wp-admin\/admin-ajax.php","nonce":"bee86d80ce","user":{"isloggedin":false,"user_type":"anon","membership_level":null,"subscribed_lists":[]},"klaviyo_lists":["sy2jg7","tkrrcd","qxiyyi","ufuy5l"]}; var block = {"obj":"{\"terms\":[],\"dynamic_ads\":[{\"advertisement_gam_id\":\"sidebar-top\",\"ad_class\":\"gam-ad-slot\",\"mobile_hide_on\":true,\"mobile_max_width\":\"874\",\"div_id\":\"sidebar-top\",\"type\":\"square\",\"slot_targeting\":{\"position\":null,\"type\":\"square\"}},{\"advertisement_gam_id\":\"sidebar-bottom\",\"ad_class\":\"gam-ad-slot\",\"mobile_hide_on\":true,\"mobile_max_width\":\"874\",\"div_id\":\"sidebar-bottom\",\"type\":\"square\",\"slot_targeting\":{\"position\":null,\"type\":\"square\"}}],\"config\":{\"ad-banner\":{\"type\":\"banner\",\"slug\":\"ad-banner\",\"sizes\":{\"small-banner\":{\"label\":\"small banner\",\"slug\":\"small-banner\",\"size\":{\"width\":320,\"height\":50}},\"medium-banner\":{\"label\":\"medium banner\",\"slug\":\"medium-banner\",\"size\":{\"width\":728,\"height\":90}}}},\"ad-square\":{\"type\":\"square\",\"slug\":\"ad-square\",\"sizes\":{\"square\":{\"label\":\"square\",\"slug\":\"square\",\"size\":{\"width\":300,\"height\":250}}}},\"ad-banner-square\":{\"type\":\"banner \\\/ square (mobile \\\/ desktop)\",\"slug\":\"ad-banner-square\",\"sizes\":{\"banner-square\":{\"label\":\"banner \\\/ square (mobile \\\/ desktop)\",\"slug\":\"banner-square\",\"size\":{\"width\":300,\"height\":250}}}},\"ad-rectangle\":{\"type\":\"rectangle\",\"slug\":\"ad-rectangle\",\"sizes\":{\"rectangle\":{\"label\":\"rectangle\",\"slug\":\"rectangle\",\"size\":{\"width\":300,\"height\":600}}}}},\"page_targeting\":{\"page_name\":\"aripiprazole or bupropion augmentation versus switching to bupropion in treatment-resistant depression: a risk-benefit analysis\",\"site_section\":\"academic_article\",\"post_type\":\"post\",\"post_id\":220339,\"permalink\":\"https:\\\/\\\/www.psychiatrist.com\\\/jcp\\\/aripiprazole-bupropion-augmentation-vs-switching-bupropion-treatment-resistant-depression-risk-benefit\\\/\",\"categories\":[\"depression\",\"early-career-psychiatrists\",\"original-research\"],\"journal\":\"jcp\"},\"page_ads\":[]}"}; window.usercontext = { isloggedin: false, hasemail: false, usertype: '' }; (function(){function c(){var b=a.contentdocument||a.contentwindow.document;if(b){var d=b.createelement('script');d.innerhtml="window.__cf$cv$params={r:'9920492c3c370384',t:'mtc2mta0ndc4oq=='};var a=document.createelement('script');a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getelementsbytagname('head')[0].appendchild(a);";b.getelementsbytagname('head')[0].appendchild(d)}}if(document.body){var a=document.createelement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendchild(a);if('loading'!==document.readystate)c();else if(window.addeventlistener)document.addeventlistener('domcontentloaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readystate&&(document.onreadystatechange=e,c())}}}})();

## Discussion
article information clinical points the journal of clinical psychiatry depression (mdd) original research early career psychiatrists september 22, 2025 aripiprazole or bupropion augmentation versus switching to bupropion in treatment-resistant depression: a risk-benefit analysis william u. meyerson, md, phd ; eric l. ross, md ; chris j. kennedy, phd, mpa ; rick h. hoyle, phd ; jagpreet chhatwal, phd ; philip s. wang, md, drph ; jordan w. smoller, md, scd j clin psychiatry 2025;86(4):25m15863 abstract objective: in treatment-resistant depression (trd), augmentation with aripiprazole (a-ari) or combination therapy by adding bupropion (c-bup) has been reported as more effective than switching to bupropion (s-bup), but c-bup risks falls in older adults, and a-ari risks weight gain and tardive dyskinesia (td). the aim of this study was to clarify whether the enhanced effectiveness outweighs such risks. methods: in this risk-benefit decision analysis, lifetime quality-adjusted life-years (qalys) following 1 year of a-ari or c-bup vs s-bup treatment were simulated in a health-state transition model tracking depression remission, falls, weight gain, and td, in age and baseline body mass index (bmi) subgroups, using data from the vast-d and optimum trials and other literature. qalys were converted to depression-free day-equivalents (dfds), the qalys gained from 1 day of remitted versus active depression. results: simulated adults aged 18–64 years experienced a net benefit of c-bup over s-bup of 20.7 dfds, equivalent to about 3 weeks of faster remission of depressive symptoms. in older adults, especially those aged 85+ years, this benefit over s-bup was partially but not fully offset by a risk of falls. in adults aged 18–64 years, a-ari was estimated to offer only 8.0 dfds after subtracting the expected harms from td, and this was further reduced to −22.8 dfds once metabolic harms were considered, in those overweight at baseline. overall, c-bup was preferred over a-ari in all subgroups except ages 85–89 years with bmi&lt;25, in whom a-ari was preferred. conclusion: in our model, c-bup better balanced efficacy and tolerability in trd in adults under 85 years than did s-bup or a-ari. a-ari was least-preferred in overweight adults. these results may inform shared decision-making and clinical guidelines. j clin psychiatry 2025;86(4):25m15863 author affiliations are listed at the end of this article. members only content this full article is available exclusively to professional tier members. subscribe now to unlock the html version and gain unlimited access to our entire library plus all pdfs. if you’re already a subscriber, please log in below to continue reading. subscribe now already a member? log in references (52) gaynes bn, lux l, gartlehner g, et al. defining treatment-resistant depression. depress anxiety . 2020;37(2):134–145. pubmed crossref zhdanava m, pilon d, ghelerter i, et al. the prevalence and national burden of treatment-resistant depression and major depressive disorder in the united states. j clin psychiatry . 2021;82(2):20m13699. pubmed crossref hantouche e, angst j, azorin jm. explained factors of suicide attempts in major depression. j affect disord . 2010;127(1-3):305–308. pubmed crossref dunner dl, rush aj, russell jm, et al. prospective, long-term, multicenter study of the naturalistic outcomes of patients with treatment-resistant depression. j clin psychiatry . 2006;67(5):688–695. pubmed crossref fekadu a, wooderson sc, markopoulo k, et al. what happens to patients with treatment-resistant depression? a systematic review of medium to long term outcome studies. j affect disord . 2009;116(1–2):4–11. pubmed crossref johnston km, powell lc, anderson im, et al. the burden of treatment-resistant depression: a systematic review of the economic and quality of life literature. j affect disord . 2019;242:195–210. pubmed crossref the national institute for health and care excellence. depression in adults: treatment and management. nice; 2022. https://www.nice.org.uk/guidance/ accessed september 30, 2024. gelenberg aj, freeman mp, markowitz jc, et al. american psychiatric association practice guideline for the treatment of patients with major depressive disorder, third edition. am j psychiatry . 2010;167(suppl):1–152. pubmed mcquaid jr, buelt a, capaldi v, et al. the management of major depressive disorder: synopsis of the 2022 u.s. department of veterans affairs and u.s. department of defense clinical practice guideline. ann intern med . 2022;175(10):1440–1451. pubmed crossref mohamed s, johnson gr, chen p, et al. effect of antidepressant switching vs augmentation on remission among patients with major depressive disorder unresponsive to antidepressant treatment: the vast-d randomized clinical trial. jama . 2017;318(2):132–145. pubmed crossref lenze ej, mulsant bh, roose sp, et al. antidepressant augmentation versus switch in treatment-resistant geriatric depression. n engl j med . 2023;388(12):1067–1079. pubmed crossref kenny ra, romero-ortuno r, kumar p. falls in older adults. medicine . 2017;45(1):28–33. haslam dw, james wpt. obesity. lancet . 2005;366(9492):1197–1209. pubmed crossref speyer h, westergaard c, albert n, et al. reversibility of antipsychotic-induced weight gain: a systematic review and meta-analysis. front endocrinol . 2021;12:577919. pubmed crossref kiriakakis v, bhatia kp, quinn np, et al. the natural history of tardive dystonia. a long-term follow-up study of 107 cases. brain . 1998;121(11):2053–2066. pubmed caroff sn, yeomans k, lenderking wr, et al. re-kinect: a prospective study of the presence and healthcare burden of tardive dyskinesia in clinical practice settings. j clin psychopharmacol . 2020;40(3):259–268. pubmed crossref yoon j, zisook s, park a, et al. comparing cost-effectiveness of aripiprazole augmentation with other “next-step” depression treatment strategies: a randomized clinical trial. j clin psychiatry . 2018;80(1):18m12294. pubmed crossref garrison lp, towse a, bresnahan bw. assessing a structured, quantitative health outcomes approach to drug risk-benefit analysis. health aff . 2007;26(3):684–695. pubmed crossref ramani sv, richard a. decision, irreversibility and flexibility: the irreversibility effect re-examined. theor decis . 1993;35(3):259–276. crossref husereau d, drummond m, augustovski f, et al. consolidated health economic evaluation reporting standards 2022 (cheers 2022) statement: updated reporting guidance for health economic evaluations . society for medical decision making; 2022. https://journals.sagepub.com/doi/full/10.1177/ accessed october 17, 2024 meyerson w, ross e, kennedy c, et al. appendix for aripiprazole or bupropion augmentation vs switching to bupropion in treatment resistant depression. 2025. https://osf.io/6czyp/ . accessed may 16, 2025 zisook s, johnson gr, hicks p, et al. continuation phase treatment outcomes for switching, combining, or augmenting strategies for treatment-resistant major depressive disorder: a vast-d report. depress anxiety . 2021;38(2):185–195. pubmed crossref bhaskaran k, dos-santos-silva i, leon da, et al. association of bmi with overall and cause-specific mortality: a population-based cohort study of 3.6 million adults in the uk. lancet diabetes endocrinol . 2018;6(12):944–953. pubmed crossref incerti d, jansen jp. hesim: health economic simulation modeling and decision analysis. 2021. doi :1 0.48550/arxiv.2102.09437 crossref attema ae, brouwer wbf, claxton k. discounting in economic evaluations. pharmacoeconomics . 2018;36(7):745–758. pubmed crossref carbon m, kane jm, leucht s, et al. tardive dyskinesia risk with first-and second-generation antipsychotics in comparative randomized controlled trials: a meta-analysis. world psychiatry . 2018;17(3):330–340. pubmed crossref morgenstern h, glazer wm. identifying risk factors for tardive dyskinesia among long-term outpatients maintained with neuroleptic medications: results of the yale tardive dyskinesia study. arch gen psychiatry . 1993;50(9):723–733. pubmed crossref woerner mg, alvir jmj, saltz bl, et al. prospective study of tardive dyskinesia in the elderly: rates and risk factors. aust j pharm . 1998;155(11):1521–1528. pubmed crossref tarsy d, lungu c, baldessarini rj. epidemiology of tardive dyskinesia before and during the era of modern antipsychotic drugs. handb clin neurol . 2011;100:601–616. pubmed crossref centers for disease control and prevention. web-based injury statistics query and reporting system (wisqars): cdc’s national center for injury prevention and control . 2002. accessed october 17, 2024. https://www.cdc.gov/injury/wisqars . tanner cm, caroff sn, cutler aj, et al. impact of possible tardive dyskinesia on physical wellness and social functioning: results from the real-world re-kinect study. j patient-rep outcomes . 2023;7(1):21. pubmed crossref ayyagari r, goldschmidt d, zhou m, et al. defining utility values for patients with tardive dyskinesia. curr med res opin . 2022;38(3):401–407. pubmed crossref mcevoy j, gandhi sk, rizio aa, et al. effect of tardive dyskinesia on quality of life in patients with bipolar disorder, major depressive disorder, and schizophrenia. qual life res . 2019;28(12):3303–3312. pubmed crossref judd ll, akiskal hs, maser jd, et al. a prospective 12-year study of subsyndromal and syndromal depressive symptoms in unipolar major depressive disorders. arch gen psychiatry . 1998;55(8):694–700. pubmed crossref mohiuddin s, payne k. utility values for adults with unipolar depression: systematic review and meta-analysis. med decis mak int j soc med decis mak . 2014;34(5):666–685. pubmed crossref revicki da, wood m. patient-assigned health state utilities for depression-related outcomes: differences by depression severity and antidepressant medications. j affect disord . 1998;48(1):25–36. pubmed crossref si l, winzenberg tm, de graaff b, palmer aj. a systematic review and meta-analysis of utility-based quality of life for osteoporosis-related conditions. osteoporos int j establ result coop eur found osteoporos natl osteoporos found usa . 2014;25(8):1987–1997. pubmed crossref ul-haq z, mackay df, fenwick e, pell jp. meta-analysis of the association between body mass index and health-related quality of life among adults, assessed by the sf-36. obes silver spring md . 2013;21(3):e322-e327 ross el, zivin k, maixner df. cost-effectiveness of electroconvulsive therapy vs pharmacotherapy/psychotherapy for treatment-resistant depression in the united states. jama psychiatry . 2018;75(7):713–722. pubmed crossref nuñez na, joseph b, pahwa m, et al. augmentation strategies for treatment resistant major depression: a systematic review and network meta-analysis. j affect disord . 2022;302:385–400. pubmed cheon ej, lee kh, park yw, et al. comparison of the efficacy and safety of aripiprazole versus bupropion augmentation in patients with major depressive disorder unresponsive to selective serotonin reuptake inhibitors: a randomized, prospective, open-label study. j clin psychopharmacol . 2017;37(2):193–199. pubmed crossref berman rm, thase me, trivedi mh, et al. long-term safety and tolerability of open-label aripiprazole augmentation of antidepressant therapy in major depressive disorder. neuropsychiatr dis treat . 2011;7:303–312. pubmed crossref barton bb, segger f, fischer k, et al. update on weight-gain caused by antipsychotics: a systematic review and meta-analysis. expert opin drug saf . 2020;19(3):295–314. pubmed crossref joo jh, lenze ej, mulsant bh, et al. risk factors for falls during treatment of late-life depression. j clin psychiatry . 2002;63(10):936–941. pubmed crossref jang sn, cho si, oh sw, et al. time since falling and fear of falling among community-dwelling elderly. int psychogeriatr . 2007;19(6):1072–1083. pubmed crossref katsoulis m, lai ag, diaz-ordaz k, et al. identifying adults at high-risk for change in weight and bmi in england: a longitudinal, large-scale, population-based cohort study using electronic health records. lancet diabetes endocrinol . 2021;9(10):681–694. pubmed crossref leucht s, cipriani a, spineli l, et al. comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. lancet . 2013;382(9896):951–962. pubmed crossref rhee tg, mohamed s, rosenheck ra. antipsychotic prescriptions among adults with major depressive disorder in office-based outpatient settings: national trends from 2006 to 2015. j clin psychiatry . 2018;79(2):17m11970. pubmed crossref gerhard t, akincigil a, correll cu, et al. national trends in second generation antipsychotic augmentation for non-psychotic depression. j clin psychiatry . 2014;75(5):490–497. pubmed crossref wang y, beydoun ma, min j, et al. has the prevalence of overweight, obesity and central obesity levelled off in the united states? trends, patterns, disparities, and future projections for the obesity epidemic. int j epidemiol . 2020;49(3):810–823. pubmed crossref luppino fs, de wit lm, bouvy pf, et al. overweight, obesity, and depression: a systematic review and meta-analysis of longitudinal studies. arch gen psychiatry . 2010;67(3):220–229. pubmed crossref fava m. lessons learned from the va augmentation and switching treatments for improving depression outcomes (vast-d) study. jama . 2017;318(2):126–128. pubmed crossref about the authors william u. meyerson, md, phd center for precision psychiatry, massachusetts general hospital, boston, massachusetts department of psychiatry, massachusetts general hospital/harvard medical school, boston, massachusetts corresponding author: william u. meyerson, md, phd, department of psychiatry, massachusetts general hospital/harvard medical school, simches research center, 185 cambridge st, boston, ma 02114 ( [email&#160;protected] ). view full profile eric l. ross, md department of psychiatry, larner college of medicine, university of vermont, burlington, vermont view full profile chris j. kennedy, phd, mpa center for precision psychiatry, massachusetts general hospital, boston, massachusetts department of psychiatry, massachusetts general hospital/harvard medical school, boston, massachusetts harvard medical school, boston, massachusetts view full profile rick h. hoyle, phd department of psychology and neuroscience, duke university, durham, north carolina view full profile jagpreet chhatwal, phd institute for technology assessment, massachusetts general hospital, harvard medical school, boston, massachusetts center for health decision science, harvard university, boston, massachusetts view full profile philip s. wang, md, drph division of pharmacoepidemiology and pharmacoeconomics, brigham and women’s hospital, harvard medical school, boston, massachusetts view full profile jordan w. smoller, md, scd center for precision psychiatry, massachusetts general hospital, boston, massachusetts department of psychiatry, massachusetts general hospital/harvard medical school, boston, massachusetts psychiatric and neurodevelopmental genetics unit, center for genomic medicine, massachusetts general hospital, boston, massachusetts view full profile buy pdf for $40 please sign in or purchase this pdf for $40. save share cite subscribe now already a member? login related news articles weekly mind reader: postpartum depression haunts one in six moms hair loss drug exacts a mental health toll decades in the making weekly mind reader: antidepressant use in pregnancy sponsored psychcase360: choosing the right long-acting injectable for patients with schizophrenia explore two real-world schizophrenia cases with roueen rafeyan, md and melissa vitale, pmhnp as they discuss challenges with medication adherence, transitioning to long-acting injectables (lais), and personalizing treatment strategies to improve patient outcomes. related jcp articles symptom network analysis of adhd and emotional symptoms in adults burnout in psychiatric doctors before and after the covid-19 pandemic effects of interpersonal and social rhythm therapy on suicidal ideation in adults with bipolar ii depression related pcc articles precision psychiatry for depression treatment predictors of depression response in a community ect clinic efficacy of glp-1 agonists in mental disorders vol 86 • 2025 • number 3 read the current issue original research treatment use and preference in a diverse sample of women with mood disorders original research klotho and matrix metalloproteinase-9 levels and their association with inhibitory dyscontrol in adolescents with first-episode major affective disorders original research niacin-induced response in early psychosis original research early ketamine response reduces suicidal events at 3 months letter to the editor suicide risk among patients with bipolar disorder: sleep disruption versus benzodiazepine use original research effect of nature videos on the burden of caregivers of patients with dementia view current issue related articles jcp original research association of immediate postpartum anxiety with postpartum depression october 15, 2025 the prevalence of immediate postpartum anxiety (ippa) in this population was 24%, and 7.4% for severe anxiety. among women with ippa, 31.2% developed postpartum depression. marie arnal , elodie-gaëlle ngameni , sarah tebeka , et al jcp original research depression at 2 months postpartum: results from the french national perinatal survey october 8, 2025 the prevalence of postpartum depression (ppd) at 2 months was 16.7%. factors associated with ppd included age ≤29 or ≥40 years, lower levels of health literacy, and a history... alexandra doncarli , virginie demiguel , camille le ray , et al jcp original research esmethadone (rel-1017) in patients with major depressive disorder and antidepressant tachyphylaxis october 6, 2025 esmethadone may be a potentially safe and effective adjunctive treatment for patients with mdd and antidepressant tachyphylaxis. clotilde guidetti , george i. papakostas , luca pani , et al expert consensus on aripiprazole lais in clinical practice read the full report subscribe to read more articles subscribe the journal of clinical psychiatry the primary care companion for cns disorders elsewhere: about advertisers media relations reprints & permissions contact us customer support follow us: x facebook instagram linkedin sign in join the email list subscribe now privacy policy terms of use physicians postgraduate press, inc. jcp issn: online 1555-2101, print 0160-6689 pcc issn: online 2155-7780, print 2155-7772 medfair.com us patent no. 684794 © copyright 2025 | physicians postgraduate press, inc. | lifelong learning for clinicians sitemap googletag.display("static-footer"); × // wait for klaviyo to load, then add custom properties document.addeventlistener('domcontentloaded', function() { // add custom properties to klaviyo tracking if (typeof klaviyo !== 'undefined') { // method a: set custom properties on the profile klaviyo.identify({ '$email': '', // add page-specific properties 'page_diseases': ["depression (mdd)"], 'primary_disease': "depression (mdd)", 'page_topics': ["depression (mdd)"], 'page_topics_count': 1, 'page_id': 220339, 'page_author': "tnq technologies", 'page_publish_date': "2025-09-22t04:00:33-05:00", 'journal': "jcp", 'last_page_view': '2025-10-21t06:06:30-05:00' }); // method b: track a custom event with page categories klaviyo.track('viewed content', { 'page_title': 'aripiprazole or bupropion augmentation versus switching to bupropion in treatment-resistant depression: a risk-benefit analysis', 'page_url': 'https://www.psychiatrist.com/jcp/aripiprazole-bupropion-augmentation-vs-switching-bupropion-treatment-resistant-depression-risk-benefit/', 'page_type': 'post', 'page_diseases': ["depression (mdd)"], 'primary_disease': "depression (mdd)", 'page_topics': ["depression (mdd)"], 'page_topics_count': 1, 'page_id': 220339, 'page_author': "tnq technologies", 'page_publish_date': "2025-09-22t04:00:33-05:00", 'journal': "jcp", 'timestamp': '2025-10-21t06:06:30-05:00' }); } }); (function () { var c = document.body.classname; c = c.replace(/woocommerce-no-js/, 'woocommerce-js'); document.body.classname = c; })(); var ajax = {"url":"https:\/\/www.psychiatrist.com\/wp-admin\/admin-ajax.php","nonce":"bee86d80ce","user":{"isloggedin":false,"user_type":"anon","membership_level":null,"subscribed_lists":[]},"klaviyo_lists":["sy2jg7","tkrrcd","qxiyyi","ufuy5l"]}; var wc_order_attribution = {"params":{"lifetime":1.0e-5,"session":30,"base64":false,"ajaxurl":"https:\/\/www.psychiatrist.com\/wp-admin\/admin-ajax.php","prefix":"wc_order_attribution_","allowtracking":true},"fields":{"source_type":"current.typ","referrer":"current_add.rf","utm_campaign":"current.cmp","utm_source":"current.src","utm_medium":"current.mdm","utm_content":"current.cnt","utm_id":"current.id","utm_term":"current.trm","utm_source_platform":"current.plt","utm_creative_format":"current.fmt","utm_marketing_tactic":"current.tct","session_entry":"current_add.ep","session_start_time":"current_add.fd","session_pages":"session.pgs","session_count":"udata.vst","user_agent":"udata.uag"}}; var kluser = {"current_user_email":"","commenter_email":""}; var psych_ajax = {"url":"https:\/\/www.psychiatrist.com\/wp-admin\/admin-ajax.php","nonce":"bee86d80ce","assets":{"spinner":"\/wp-content\/themes\/psych\/assets\/images\/spinner.gif","checkmark_white":"\/wp-content\/themes\/psych\/assets\/images\/icons\/check-white.svg","checkmark_tertiary":"\/wp-content\/themes\/psych\/assets\/images\/icons\/check-tertiary.svg","share":"\/wp-content\/themes\/psych\/assets\/images\/icons\/share.svg","quote":"\/wp-content\/themes\/psych\/assets\/images\/icons\/quote.svg","bookmark":"\/wp-content\/themes\/psych\/assets\/images\/icons\/bookmark-white.svg","bookmark_tertiary":"\/wp-content\/themes\/psych\/assets\/images\/icons\/bookmark-tertiary.svg"}}; var psych_ajax = {"url":"https:\/\/www.psychiatrist.com\/wp-admin\/admin-ajax.php","nonce":"bee86d80ce","assets":{"spinner":"\/wp-content\/themes\/psych\/assets\/images\/spinner.gif","checkmark_white":"\/wp-content\/themes\/psych\/assets\/images\/icons\/check-white.svg","checkmark_tertiary":"\/wp-content\/themes\/psych\/assets\/images\/icons\/check-tertiary.svg","share":"\/wp-content\/themes\/psych\/assets\/images\/icons\/share.svg","quote":"\/wp-content\/themes\/psych\/assets\/images\/icons\/quote.svg","bookmark":"\/wp-content\/themes\/psych\/assets\/images\/icons\/bookmark-white.svg","bookmark_tertiary":"\/wp-content\/themes\/psych\/assets\/images\/icons\/bookmark-tertiary.svg"}}; var ajax = {"url":"https:\/\/www.psychiatrist.com\/wp-admin\/admin-ajax.php","nonce":"bee86d80ce","user":{"isloggedin":false,"user_type":"anon","membership_level":null,"subscribed_lists":[]},"klaviyo_lists":["sy2jg7","tkrrcd","qxiyyi","ufuy5l"]}; var block = {"obj":"{\"terms\":[],\"dynamic_ads\":[{\"advertisement_gam_id\":\"sidebar-top\",\"ad_class\":\"gam-ad-slot\",\"mobile_hide_on\":true,\"mobile_max_width\":\"874\",\"div_id\":\"sidebar-top\",\"type\":\"square\",\"slot_targeting\":{\"position\":null,\"type\":\"square\"}}],\"config\":{\"ad-banner\":{\"type\":\"banner\",\"slug\":\"ad-banner\",\"sizes\":{\"small-banner\":{\"label\":\"small banner\",\"slug\":\"small-banner\",\"size\":{\"width\":320,\"height\":50}},\"medium-banner\":{\"label\":\"medium banner\",\"slug\":\"medium-banner\",\"size\":{\"width\":728,\"height\":90}}}},\"ad-square\":{\"type\":\"square\",\"slug\":\"ad-square\",\"sizes\":{\"square\":{\"label\":\"square\",\"slug\":\"square\",\"size\":{\"width\":300,\"height\":250}}}},\"ad-banner-square\":{\"type\":\"banner \\\/ square (mobile \\\/ desktop)\",\"slug\":\"ad-banner-square\",\"sizes\":{\"banner-square\":{\"label\":\"banner \\\/ square (mobile \\\/ desktop)\",\"slug\":\"banner-square\",\"size\":{\"width\":300,\"height\":250}}}},\"ad-rectangle\":{\"type\":\"rectangle\",\"slug\":\"ad-rectangle\",\"sizes\":{\"rectangle\":{\"label\":\"rectangle\",\"slug\":\"rectangle\",\"size\":{\"width\":300,\"height\":600}}}}},\"page_targeting\":{\"page_name\":\"aripiprazole or bupropion augmentation versus switching to bupropion in treatment-resistant depression: a risk-benefit analysis\",\"site_section\":\"academic_article\",\"post_type\":\"post\",\"post_id\":220339,\"permalink\":\"https:\\\/\\\/www.psychiatrist.com\\\/jcp\\\/aripiprazole-bupropion-augmentation-vs-switching-bupropion-treatment-resistant-depression-risk-benefit\\\/\",\"categories\":[\"depression\",\"early-career-psychiatrists\",\"original-research\"],\"journal\":\"jcp\"},\"page_ads\":[]}"}; var ajax = {"url":"https:\/\/www.psychiatrist.com\/wp-admin\/admin-ajax.php","nonce":"bee86d80ce","user":{"isloggedin":false,"user_type":"anon","membership_level":null,"subscribed_lists":[]},"klaviyo_lists":["sy2jg7","tkrrcd","qxiyyi","ufuy5l"]}; var block = {"obj":"{\"terms\":[],\"dynamic_ads\":[{\"advertisement_gam_id\":\"sidebar-top\",\"ad_class\":\"gam-ad-slot\",\"mobile_hide_on\":true,\"mobile_max_width\":\"874\",\"div_id\":\"sidebar-top\",\"type\":\"square\",\"slot_targeting\":{\"position\":null,\"type\":\"square\"}},{\"advertisement_gam_id\":\"sidebar-bottom\",\"ad_class\":\"gam-ad-slot\",\"mobile_hide_on\":true,\"mobile_max_width\":\"874\",\"div_id\":\"sidebar-bottom\",\"type\":\"square\",\"slot_targeting\":{\"position\":null,\"type\":\"square\"}}],\"config\":{\"ad-banner\":{\"type\":\"banner\",\"slug\":\"ad-banner\",\"sizes\":{\"small-banner\":{\"label\":\"small banner\",\"slug\":\"small-banner\",\"size\":{\"width\":320,\"height\":50}},\"medium-banner\":{\"label\":\"medium banner\",\"slug\":\"medium-banner\",\"size\":{\"width\":728,\"height\":90}}}},\"ad-square\":{\"type\":\"square\",\"slug\":\"ad-square\",\"sizes\":{\"square\":{\"label\":\"square\",\"slug\":\"square\",\"size\":{\"width\":300,\"height\":250}}}},\"ad-banner-square\":{\"type\":\"banner \\\/ square (mobile \\\/ desktop)\",\"slug\":\"ad-banner-square\",\"sizes\":{\"banner-square\":{\"label\":\"banner \\\/ square (mobile \\\/ desktop)\",\"slug\":\"banner-square\",\"size\":{\"width\":300,\"height\":250}}}},\"ad-rectangle\":{\"type\":\"rectangle\",\"slug\":\"ad-rectangle\",\"sizes\":{\"rectangle\":{\"label\":\"rectangle\",\"slug\":\"rectangle\",\"size\":{\"width\":300,\"height\":600}}}}},\"page_targeting\":{\"page_name\":\"aripiprazole or bupropion augmentation versus switching to bupropion in treatment-resistant depression: a risk-benefit analysis\",\"site_section\":\"academic_article\",\"post_type\":\"post\",\"post_id\":220339,\"permalink\":\"https:\\\/\\\/www.psychiatrist.com\\\/jcp\\\/aripiprazole-bupropion-augmentation-vs-switching-bupropion-treatment-resistant-depression-risk-benefit\\\/\",\"categories\":[\"depression\",\"early-career-psychiatrists\",\"original-research\"],\"journal\":\"jcp\"},\"page_ads\":[]}"}; window.usercontext = { isloggedin: false, hasemail: false, usertype: '' }; (function(){function c(){var b=a.contentdocument||a.contentwindow.document;if(b){var d=b.createelement('script');d.innerhtml="window.__cf$cv$params={r:'9920492c3c370384',t:'mtc2mta0ndc4oq=='};var a=document.createelement('script');a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getelementsbytagname('head')[0].appendchild(a);";b.getelementsbytagname('head')[0].appendchild(d)}}if(document.body){var a=document.createelement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendchild(a);if('loading'!==document.readystate)c();else if(window.addeventlistener)document.addeventlistener('domcontentloaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readystate&&(document.onreadystatechange=e,c())}}}})();

## Scraping Notes

- Successfully scraped from DOI.org
